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CD8+ T cell responses are crucial for immunity against intracellular infections and can mediate tumor 
regression. While CD8+ T cells are widely recognized as cytolytic effector cells (cytolytic T cells; CTLs), 
little is known about their immunoregulatory functions and their impact on dendritic cells (DCs). A 
similar area of controversy is the role of DC in regulating the induction of CD8+ T cell effector functions 
and CD8+ T cell memory. This dissertation addresses the impact of bidirectional communication between 
DCs and CD8+ T cells, during different phases of the immune response, upon the functions of both these 
cell types.  
In order to reconcile the apparently contrasting notions that CD8+ T cells perform both 
“suppressor” and “helper” functions, I compared the DC-modulating activity of CD8+ T cells at different 
stages of activation. I observed that DC-killing and DC-activating (and protective) functions are exerted 
sequentially by activated CD8+ T cells. In contrast to the effector cells that kill DCs in a granzyme 
B/perforin-dependent manner, memory CD8+ T cells promote IL-12 production in DCs and support CD4+ 
and CD8+ T cell responses. Moreover, memory CD8+ T cells instruct DC to over-express granzyme B 
inhibitor PI-9, protecting them from elimination by CTLs. I observed that the inclusion of “heterologous” 
CD8+ T cell epitopes in cancer vaccines, promoting the interaction of vaccine-bearing DCs with large 
numbers of tumor-unrelated CD8+ T cells, strongly enhances the immunologic and therapeutic activity of 
vaccination against established tumors that are resistant to standard vaccines. 
Since the character of the vaccination-induced CD8+ T cells is important for the efficacy of 
cancer immunotherapy, I have analyzed the role of DCs in influencing the cytolytic function and 
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peripheral tissue-homing ability of CD8+ T cells. I observed that short-term-activated “inflammatory-
type” DCs, capable of producing high levels of IL-12 and other pro-inflammatory cytokines, support 
induction of cytotoxic function and a switch from lymphoid to peripheral chemokine receptors in CD8+ T 
cells. In contrast, “exhausted” DCs matured for extended periods of time or matured under the influence 
of the mediators of chronic inflammation, favor CD8+ T cell expansion alone without acquisition of 
effector functions. 
Collectively, the findings presented in this dissertation broaden our understanding of the feedback 
circuitry between CD8+ T cells and DCs and will help us to design improved vaccines against cancer and 
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CD8+ T lymphocytes are an important component of a host’s immune response to intracellular 
infections and malignant tumors. CD8+ T cells use multiple cytotoxic effector mechanisms such 
as perforin/granzyme and Fas-FasL to mediate the elimination of infected and transformed cells 
(1, 2). In addition, CD8+ T cells exert non-cytotoxic effector pathway through the release of 
effector cytokines such as IFNγ and TNFα that block viral gene expression, recruit and activate 
macrophages and NK cells and upregulate antigen processing machinery and MHC expression in 
the infected cells(3, 4). Once a primary infection is resolved or brought under control, progeny of 
antigen-specific CD8+ T cells develop into memory CD8+ T cells. These memory cells have the 
ability to rapidly regain effector functions when re-exposed to antigen, thereby providing long–
lasting protective immunity. The generation of a robust CD8+ T cell response involves priming 
of naïve CD8+ T cells by dendritic cells (DCs), the professional antigen presenting cells of the 
immune system. Activated DCs can provide naïve T cells with antigen-specific T cell activating 
“signal 1”, costimulatory “signal 2” determining the magnitude of immune response and 
polarizing “signal 3” obtained from the peripheral environment activating the DCs and in turn 
affecting the character of the immune response. It is the dynamic interaction between naïve CD8+ 
T cells and dendritic cells (DCs) that lead to generation of effector and memory CD8+ T cells.  
Until recently, the biology of CD8+ T cells was focused on elaborating their role as 
cytotoxic effector cells in different infection models. Many questions remained unanswered 
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about the role of effector and memory CD8+ T cells in regulating the immune response. In this 
dissertation, we investigate the functional impact of positive and negative feedback signals 
arising from memory and effector CD8+ T cells on the magnitude and quality of DC-mediated 
immune responses. While the pathway of generation of effector and memory cells has been 
studied extensively, the models that have been proposed are apparently conflicting with regard to 
lineage relationship between effector and memory subsets. I attempt to address this problem and 
have focused on the conditions of DC maturation as a determining factor for regulating the 
acquisition of effector functions and tissue-homing ability. Before presenting a detailed 
exposition on the immunoregulatory functions of CD8+ T cells and the influence of DC 
maturation on the differentiation of CD8+ T cells, I briefly summarize the diverse functions of 
CD8+  T cells performed in the course of an immune response. 
1.1  CD8+ T LYMPHOCYTES AS CYTOLYTIC EFFECTOR CELLS 
Several studies collectively suggest that activation and expansion of naïve CD8+ T cells can be 
initiated by a brief exposure to antigen (5, 6) (7, 8). For example, a two hour exposure of CD8+ T 
cells to antigen in vitro is sufficient to induce proliferation and 24 hours of antigen exposure in 
vivo is sufficient to drive multiple rounds of divisions and induction of effector and memory 
populations. In addition to antigen, other signals such as inflammatory cytokines induced either 
by pathogen itself or by immunization in the presence of strong adjuvants can influence the 
differentiation program.  The outcome of CD8+ T cell differentiation program is the acquisition 
of cytolytic function and peripheral homing ability, and we discuss the regulation of these two 
aspects in the following subsections.  
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1.1.1 Role of signal 3 in development of effector functions 
Previous studies have shown that generation of effective immune response against antigen 
requires co-injection of molecules with adjuvant activity (9). Adjuvants serve as danger signals, 
and the immune system has evolved to recognize and respond to such signals that indicate 
infection or cell damage (10, 11). Microbial stimuli (12) as well as pathogen-induced factors 
such as IFNγ and PGE2 (13) can modulate the DC derived T-cell-polarizing signals (signal 3) 
such as IL-12 family members and type 1 interferons (13). 
Both human in vitro and mouse in vivo studies have demonstrated that naïve CD4+ T cell 
differentiation can be uncoupled from proliferation (14-16). The absence of T-cell-polarizing 
signal 3 during the priming of naïve CD4+ T cells resulted in CD4+ T cell proliferation alone 
without differentiation into Th1 or Th2 pathway. While detailed study for CD8+ T cells has not 
been done, there is increasing evidence suggesting the role of signal 3 in the development of 
cytolytic function. The study from Mescher’s group indicates that exposure of naïve CD8+ T 
cells to artificial APC (antigen and B7) and IL-12  enhances T cell cytolytic function compared 
to T cells stimulated in the absence of IL-12 (17, 18). In vivo studies with peptide immunization 
demonstrated that IL-12 worked as good as CFA in promoting full activation of CD8+ T cells 
(19). Another inflammatory cytokine involved in promoting CD8+ T cell expansion and survival 
is type I IFN (20). In addition, data from a human clinical trial using a combination of ALVAC 
vaccine and high dose IFNα also indicated the role of IFNα in the development of CTL function. 
The patients receiving high dose IFNα treatment following ALVAC vaccine showed enhanced 
in vitro anti-tumor responses and tumor regression in vivo (21). Together these observations 
suggest that in addition to antigen and co-stimulation, a third signal is required to induce a 
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complete differentiation program in CD8+ T cells. Pathogen or pathogen-derived product can act 
on DCs and induce the release of cytokines (IL-12, IFN-α/β) which function as third signal, 
consequently making DCs a crucial link in the development of effector T cell responses. 
1.1.2 Role of dendritic cells in the development of T cell effector functions 
There are distinct DC subsets in both mouse and human and each subset exhibits a unique set of 
pathogen-recognition receptors (PRRs) allowing them to interact with distinct classes of 
pathogen. Several studies have shown that not all DCs are equally effective in inducing T cell 
differentiation. For example, results from mouse studies suggest that CD4+ T cell differentiation 
is dependent on the subset of DC involved in priming (22)(23). It has been shown that the high 
IL-12 producing CD8α+DCs and lymphoid-related DC subset CD11c+CD11bdull drive Th1 
development while CD8α-DCs and myeloid-related DC subset CD11c+CD11bbright induce Th2-
type responses.  
In addition to the intrinsic differences between subsets of DCs in their capacity to induce 
CD4+ T cell differentiation towards Th1 and Th2 pathway, results from in vitro human 
experiments have shown that different levels of DC maturation can influence the levels of IL-12 
production (14) and the outcome of T cell priming (15). Indirect evidence of the impact of DC 
maturation on CD8+ T cell priming comes from in vivo mouse experiments involving 
immunization with live versus heat-killed or inactivated virus (24, 25). The use of inactivated 
virus was shown to be associated with reduced level of DC maturation, resulting in the inability 
to develop protective immunity to influenza (26). These results are likely to be explained by 
several phenomena: reduced TLR-mediated activation of innate immune responses (27), reduced 
TLR-mediated activation of DCs, insufficient DC maturation resulting in reduced expression of 
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CD80, CD86, CD40, MHC Class II and reduced production of IFNγ (25, 28, 29). Taken 
together, these observations imply that the extent of DC maturation qualitatively affects the 
pattern of T cell differentiation. Taking cues from these studies, I have developed an in vitro 
model that allows us to study the influence of degree of DC maturation (acute activation vs. 
chronic activation) on the development of CD8+ T cell effector function and the generation of 
.memory population. 
1.1.3 Regulation of peripheral–type chemokine receptors on effector CD8+ T cells 
The differentiation program of CD8+ T cells induces two key changes: a) equips the cells with 
the necessary armament needed to perform effector functions and b) programs the cells to leave 
the lymph node (LN) and migrate appropriately to peripheral sites to carry out effector functions. 
Inflammation induced trafficking of effector cells requires imprinting of the information needed 
for migration, i.e. up-regulation of inflammatory chemokine receptors on T cells, to occur 
concurrently with activation of T cells.  
While the exact mechanisms by which DCs regulate a switch in the T cell’s 
responsiveness to LN-associated and peripheral tissue-associated chemokines is unclear, 
previous studies have shown that DCs act as source of signals that regulate the pattern of T cell 
migration. In mouse, DCs from Peyer’s patches and mesenteric lymph nodes induce gut homing 
capacity in CD8+ T cells whereas DCs from skin draining lymph node imprint skin homing-
specific selectin ligands and chemokine receptors (30). These results demonstrate the role of DCs 
in influencing the expression of chemokine receptors, but it remains unclear how different levels 
and modes of DC maturation affect chemokine receptor programming.  
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1.2   IMMUNOREGULATION BY EFFECTOR CD8+ T CELLS  
Cytotoxicity is a defining characteristic of the effector CD8+ T cells (31). Although previous 
studies indicate suppressor activity for CD8+ T cells, the mechanism for such immunoregulatory 
function remains unclear (32, 33). One of the early experiments on suppressor activity studied 
the feed-back suppression by effector T cells as a way of regulating the primary response to 
ectromelia virus infection (34). More recent studies using mouse infection models (Listeria, 
LCMV, malaria and HSV) demonstrate that activated CD8+ T cells limit the CTL response by 
regulating the duration of antigen display (35, 36). This self-limiting feature of activated CD8+ T 
cell operates in murine models through elimination of DC in a perforin-dependent manner (37), 
although other mechanisms such as Fas-FasL mediated killing and the involvement of NK cell-
like receptors NKp30 and NKp46 cannot be ruled out. The site of DC killing is debatable. 
Depending on the experimental setup both inflamed lymph nodes and peripheral tissues have 
been proposed to be the sites of DC killing (37, 38). Understanding the relation of CTL-mediated 
DC killing to the generation of secondary immune response will aid in designing vaccines for 
chronic infections and cancer.  
1.3 DUAL ROLE OF EFFECTOR CD8+ T CELLS 
The cytolytic activity of effector CD8+ T cells has two important roles: it is essential for the 
overall level of immunity by directly eliminating the infected or transformed cells, and also for 
suppressing immune responses by eliminating the antigen-carrying DCs. In this dissertation, I 
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will explore the mechanism of the regulatory function of cytolytic effector CD8+ T cells and will 
analyze how DCs can resist such an attack. 
1.4 TCR-INDEPENDENT FUNCTIONS OF PRIMED CD8+ T CELLS 
CD8+ T cells are not generally associated with innate immune response and execute their effector 
functions only upon TCR triggering. Interestingly however, recent observations in murine 
infection models (Listeria, Shigella, Burkholderia) suggest the involvement of primed CD8+ T 
cells in early phases of the innate immune response in a non-TCR dependent manner (39,40, 41). 
Direct evidence from the Listeria infection model indicate that TCR-independent but cytokine-
mediated secretion of IFNγ by memory CD8+ T cells can provide early protection against LM 
(42). Early innate response of CD8+ T cells is induced by the concerted action of IL-12 and IL-
18, both of which are secreted early on in the infection by infected macrophages and DCs (43, 
44). Moreover, primed CD8+ T cells have been shown to upregulate the receptors for IL-12 and 
IL-18 (45). Since the ability of primed CD8+ T cells to participate in the innate response can be 
important for immunopathology and therapy, my objective in this thesis is to understand the 
regulatory mechanism of non-TCR inducible functions, and study their influence on promoting 
the local immune response.  
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1.5 IMMUNE MEMORY AND MEMORY CD8+ T CELLS  
CD8+ T cells perform different functions at different time points of the immune response. 
Following the effector stage of the immune response, CD8+ T cells progress towards a period of 
quiescence and homeostatic proliferation, leading to the development of a memory population.  
Memory CD8+ T cells are the antigen-experienced cells and are crucial for the success of 
T-cell based protective vaccination strategies. The cardinal features of memory CD8+ T cells 
include their ability to persist over prolonged periods of time and to rapidly regain effector 
functions upon re-exposure to the same antigen (46, 47). Two questions essential for vaccine-
related research are: a) identifying mechanisms by which memory CD8+ T cells are formed and 
maintained over long periods of time and, b) the mechanism of their contribution to secondary 
immune responses.  
Much effort has been devoted to understanding the differentiation pathway from naïve to 
memory CD8+ T cells. Several conflicting models have been proposed to explain the T-cell 
differentiation. The first is a linear progression model (Fig.1.1A), where CD8+ T cells 
differentiate from naïve to effector to memory CD8+ T cells (48, 49). According to this model, 
memory cells represent the progeny of the effector cells that escape Activation Induced Cell 
Death (AICD). This model has been supported by data from adoptive transfer experiments using 
TCR transgenic CD8+ T cells. The second is a branched model of CD8+ T cell differentiation 
(Fig. 1.1B), where memory and effector cells simultaneously develop from a common precursor, 
but as separate lineages (50). Recent observations from Chang et al (51) provide a potential 
mechanism for the branched model of differentiation. Following a sustained interaction between 
naïve T cell and DCs, naïve T cells undergo an asymmetric first division giving rise to proximal 
daughter cell which can potentially receives more antigen and costimulation compared to the 
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distal cell. Accordingly the first proximal daughter cell could represent effector lineage while 















Figure  1.1 Linear progression and branched model of CD8+ T cell differentiation (based on (49, 50).  
(A) According to the linear model of differentiation, memory T cells are derived from effector cells that escape 
AICD and revert to quiescence state. (B) According to the branched model of differentiation, the duration of 
antigenic stimulation and type of cytokines present during priming lead to differentiation either into effectors cells 
or memory cells. 
 
The progressive differentiation model was developed by Lanzavecchia and colleagues by 
incorporating signal strength as the factor governing differentiation of T cells (52) into effector 
or memory pathway. According to this model (Fig. 1.2), depending on the strength of TCR and 
costimulatory signals, responding T cells acquire effector functions, tissue-homing receptors and 
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responsiveness to homeostatic cytokines. While high signal strength allows acquisition of 
effector functions and gain of tissue-homing capacity, low signal strength results in retention of 










Figure  1.2  Progressive differentiation model for CD8+ T cells (based on (52).  
Hierarchical thresholds of signal strength induce naïve CD8+ T cells to proliferate, acquire effector functions and to 
change their migratory capacity. The increasing signal strength is depicted by the increasing thickness of the arrow. 
At the increasing strength of stimulation, the responding T cells proliferate, acquire responsiveness to homeostatic 
cytokines, develop effector functions and lose lymphoid homing receptor (CCR7). 
 
Similar to the signal strength-based model (52), in vivo observations using the model of 
chronic viral infections (53) resulted in formulation of the Goldilocks model of T cell 
differentiation (Fig. 1.3). According to this model, weak stimulation leads to expanded T cells 
that are unfit and rapidly die while strong stimulation allows differentiation of CD8+ T cells and 
the development of memory cells. Furthermore, prolonged or very strong stimulation causes 
aberrant differentiation of cells without the development of memory cells.  
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Figure  1.3 Goldilocks model for CD8+ T cell differentiation (based on (53). 
Weak antigenic stimulation leads to limited CD8+ T cell expansion and poor memory development and attrition of 
unfit cells. Optimum memory development is favored when conditions are just right; that is strong antigenic 
stimulation leads to T cell proliferation and differentiation into tissue-homing effectors. Upon antigen clearance, the 
fittest expanded cells survive as central-memory and effector memory T cells. Chronic antigen exposure drives 
continuous proliferation of T cell and differentiation into effectors. The effector T cells progressively lose the ability 
to secrete cytokines and eventually get eliminated. 
 
While these models explain the pathway of CD8+ T cell differentiation, there are two 
parameters that are not explicitly taken into account in any of these models. The first parameter 
is the inflammatory milieu associated with differentiation of CD8+ T cells. The second parameter 
is the time-point of the interaction of CD8+ T cells with antigen presenting cells, and the 
potential difference in the  outcome of  priming occurring during early stages of infection 
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(antigen, costimulation, and inflammatory milieu) versus late stages of infection (antigen and 
inflammatory milieu disappearing).  
1.5.1 Inflammation and development of memory CD8 + T cells: an inverse relation 
There is increasing evidence suggesting an inverse correlation between the level of inflammation 
and development of memory CD8+ T cells (48, 54). Indirect evidence from mouse studies reveals 
the need for early inflammation following infection or DC immunization in order to generate a 
robust effector response. The antibiotic treatment (after infection), reducing the active phase of 
pathogen activity and the level of resulting inflammation (55) (56), has been shown to accelerate 
the formation of CD8+ memory T cells in mouse. Depending on the nature of infection - acute 
versus persistent, varying differentiation phenotypes of CD8+ T cells have been observed in 
humans. Following an acute infection characterized by transient inflammation, such as influenza 
or measles, long-lasting memory population of CD8+ T cells is generated (57). In contrast, 
chronic infections such as CMV and HCV result in persistent inflammation and reduced 
development of functional memory cells (58). The involvement of inflammation in 
differentiation of CD8+ T cell is also reflected in the results from several of the human cancer 
immunotherapy trials (59), where most DC- or peptide-based vaccinations induce massive 
expansion of tumor-specific CD8+ T cells but modest induction of effector functions. More work 
is certainly required to broaden our understanding of the relationship between inflammation and 
generation of the memory population. 
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1.5.2 Novel function of memory CD8+ T cells  
Antigen-experience gives memory CD8+ T cells, a unique ability to mediate rapid, stronger, and 
more effective response to secondary pathogen challenge than naïve cells. Protective immune 
memory can persists for years after initial antigenic exposure, in humans CD8+ memory T cells 
can be maintained for up to 75 years after vaccination (60). Memory CD8+ T cells are less 
dependent on co-stimulation and cytokines to reacquire effector functions, which partly explains 
their ability to respond to the pathogens more rapidly than naïve cells. Moreover, the ability of 
memory CD8+ T cell to recognize the pathogen and secrete cytokines before the onset of 
infection-induced inflammation and damage can potentially be used as a warning sign and as an 
alternate source of pathogen information. The information directly provided by the pathogen 
through PRR is misleading for the immune system in certain instances for example; both 
Candida albicans and Bordetella pertussis use TLR2 signaling as an escape strategy to induce 
DC production of IL-10, resulting in the development of antigen-specific Tregs.  
In contrast to the effector cells, memory cells have been shown to lack immediate DC-
killing activity and there is no direct evidence that demonstrates the particular role of memory 
CD8+ T cells in immunoregulation. However, observations from mice and human studies suggest 
that prior infection influences the character of the immune response generated by subsequent 
infection. For example, mice infected with murine helminth Heilgmosomoides polygrus prior to 
infection with Helicobacter felis have significant reduction in gastric expression of type 1 
cytokines such as IFNγ and TNFα and higher expression of IL-4, IL-10 and TGFβ (61). There 
are several examples of human infections that can modulate the immune response elicited to 
subsequent infection, for example helminthic infections are associated with suppressed IFNγ 
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responses to tuberculin antigen (62). Similarly, infections with mycobacteria, measles virus or 
gastrointestinal pathogens have all shown to be inversely correlated with the risk of atopy and 
IgE-dominated responses to different allergens (63-65). These observations suggest the 
possibility of immune system learning from past infections and using that information to 
modulate subsequent immune responses. My objective in this dissertation is to explore the role 
of memory CD8+ T cells and DCs in this learning process.  
1.5.3 DC as mediator of CD8+ T cell dependent immunomodulation 
Dendritic cells are optimally positioned at the anatomical sites of potential pathogen entry 
allowing them to sense and capture the antigenic material (66). In addition, DCs are flexible 
mediators of environmental signals and the only cell type that is capable of effectively priming 
naïve T cells in the lymph nodes (67). Since DCs are both the carriers of pathogenic information 
and the orchestrators’ of immune response, I explore the idea of memory CD8+ T cells using 
their own antigen experience to educate the DCs about the pathogen location (extracellular or 
intracellular) and what effector mechanism to use to eliminate pathogen rather than what the 
specific pathogen may be. As discussed in the dissertation, this education ensures that the 






1.6 SCOPE OF THIS DISSERTATION 
The scope of this dissertation is to identify the immunoregulatory roles of effector and memory 
CD8+ T cells in the development of DC-mediated immune responses and the role of DC in 
development of effector and memory CD8+ T cells.  
The mouse model of DC-based cancer vaccination described in Chapter 2 was designed 
to segregate regulatory functions of CD8+ T cells from their effector activities in vivo. We were 
able to demonstrate that regulatory suppressor and helper functions represent sequential phases 
of CD8+ T cell responses to peptide antigens. Our data demonstrate the ability of resting CD8+ 
memory T cells to act as helper cells, providing DC-mediated helper signals that support the 
development of functional CTL responses. The current results show that the inclusion in cancer 
vaccines of “heterologous helper epitopes”, promoting the interaction of DCs with high numbers 
of tumor-unrelated memory-type CD8+ T cells, enhances the immunologic and therapeutic 
effectiveness of vaccination against established tumors.  In Chapter 3, I used human in vitro 
models to study the mechanisms of the effector CD8+ T cell-mediated suppression and memory 
CD8+ T cell-mediated helper function during the de novo development of functional CTL and 
Th1 responses in naïve populations of CD8+ and CD4+ T cells. My data demonstrate that the 
helper function of memory CD8+ T cell includes promoting the survival and type-1 polarization 
of DCs and with TNFα and PI-9 (endogenous granzyme B inhibitor) being two key factors.  
In Chapter 4, I focus on the role of the timing of DC activation and the role of IL-12 and 
other DC-related factors in inducing the cytolytic versus non-cytolytic pathways of 
differentiation of naive CD8+ T cells. In addition, I test whether the switch in the expression of 
central and peripheral chemokine receptors on activated CD8+ T cells is regulated by the 
functional status of dendritic cells. I address these issues by maturing DCs for different periods 
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of time or in different inflammatory environments. My data demonstrate that DCs matured under 
acute inflammatory conditions (similar to acute viral infection) promote the effector pathway of 
CD8+ T cell differentiation, followed by the development of memory cells. In contrast, DCs 
matured under chronic inflammatory conditions, or over-matured “exhausted” DCs favored the 
differentiation of naïve CD8+ T cells directly into memory cells bypassing the effector stage. The 
results suggest that the differentiation of CD8+ T cells can be modulated by the character of the 
DCs.  
Since, the results of chapter 4 indicated the negative impact of the effector-type T cells 
upon DCs, in Chapter 5, I attempt to uncouple the regulatory and DC-killing functions of 
effector CTLs, by utilizing alternative means of CTL activation that are not associated with DC 
killing. I analyze the requirements for activation of primed CD8+ T cells in a TCR independent 
manner, and observed that such “alternatively-activated” CTLs activate DC but cannot kill them. 
These data suggest an additional way of utilizing the modulatory activity of the effector cells. 
In Chapter 6, I combine the findings from this work with the latest reports from other 
groups, to develop the concept of temporal and spatial separation of the regulatory suppressor 
versus helper functions of CD8+ T cells. Based on these data, I propose that the helper function 
of memory CD8+ T cells provides DC-mediated help to naïve CD8+ T cells in a manner similar 
to CD4+ T cell help, favoring effective development of T cell effector functions during 
secondary immune responses. My results help to design DC-based vaccines and vaccination 
regimens that preferentially support the generation of either cytolytic or memory T cell 
populations, in order to achieve optimal efficacy of therapeutic and preventive vaccines.  
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2 HELPER FUNCTION OF MEMORY CD8+ T CELLS: HETEROLOGOUS 
CD8+ T CELLS SUPPORT THE INDUCTION OF THERAPEUTIC CANCER 
IMMUNITY 
2.1 ABSTRACT 
In contrast to well-established efficacy of preventive vaccines, the effectiveness of therapeutic 
vaccines remains limited.  In order to develop effective vaccination regimens against cancer, we 
have analyzed the impact of effector and memory CD8+ T cells upon the ability of dendritic cells 
(DC) to mediate the immunologic and anti-tumor effects of vaccination. We show that in 
contrast to effector CD8+ T cells that kill antigen-carrying DCs, IFNγ-producing memory CD8+ 
T cells act as “helper” cells, supporting the ability of DCs to produce IL-12p70. Promoting the 
interaction of tumor antigen-carrying DCs with memory-type “heterologous” (tumor-irrelevant) 
CD8+ T cells strongly enhances the IL-12p70-dependent immunogenic and therapeutic effects of 
vaccination in the animals bearing established tumors. Our data demonstrate that suppressive and 
helper functions of CD8+ T cells are differentially expressed at different phases of CD8+ T cell 
responses. Selective performance of helper functions by memory (in contrast to effector) CD8+ T 
cells helps to explain the phenomenon of immune memory and facilitates the design of effective 




Preventive vaccines, usually composed of “priming” and “booster” doses, have proven effective 
in controlling multiple infectious diseases, but the efficacy of current therapeutic vaccines 
remains low (68-71). Successful induction of immune memory is considered to be essential for 
vaccine effectiveness, but the exact pathways of development of memory CD8+ T cells, and the 
features of their biology allowing them to mediate protection upon secondary antigen (Ag) 
challenge, remain unclear (72-75). Two long-recognized but poorly understood phenomena in 
vaccine biology include the importance of delayed application of booster doses of vaccines in 
order to achieve effective secondary T cell expansion (76) and the paradoxical contraction of the 
CD8+ T cell pool when the second antigenic exposure occurs too soon (76, 77).  
CD8+ T cells are key to our ability to control intracellular infections and cancer. They act 
as cytotoxic T lymphocytes (CTL) (78) that eliminate the infected or transformed cells, but also 
perform regulatory functions, being capable of either suppressing (36, 37, 79, 80) or supporting 
(81-84) immune responses. While the mechanism of the suppressive activity of CD8+ T cells is 
far from clear, it has been shown that perforin- and Granzyme-dependent elimination of Ag-
carrying dendritic cells (DCs) by Ag-specific CD8+ T cells (36, 37, 80, 85, 86) can act as a 
suppressive mechanism, providing a self-limiting character to CTL responses (36, 37, 80), and 
restricting the efficacy of vaccination (36, 37, 80, 85). In contrast to the long-known ability of 
CD8+ T cells to inhibit immune responses (79), it only recently became apparent that CD8+ T 
cells can also activate DCs (81-84, 87) and support type-1 immunity (81-84). Such “helper” 
function of CD8+ T cells depends on their ability to produce IFNγ and to promote the DC 
production of IL-12p70 (83, 84), the key factor supporting Th1 and CTL responses (88).  
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The relationship between the “suppressor” versus “helper” functions of CD8+ T cells 
remains unclear. Previous reports demonstrated that the suppressive effects resulting from the 
elimination of Ag-carrying DCs by CD8+ T cells are mediated by the effector but not memory 
cells (37, 80). However, the possibility that it is the memory CD8+ T cells that selectively play 
the reciprocal helper role, has never been explored.  
Here, using the model of therapeutic vaccination with tumor-loaded DCs carrying 
additional tumor-unrelated (“heterologous”) antigens, that allowed us to uncouple the regulatory 
functions of CD8+ T cells from their effector activity, we demonstrate that the “suppressor” 
versus “helper” functions represent sequential phases of CD8+ T cell responses. Our data show 
that promoting the interaction of tumor Ag-carrying DCs with memory-type CD8+ T cells 
specific for tumor-unrelated Ags promotes the therapeutic activity of vaccination against the 
established tumors that are resistant to standard vaccines. 
2.3 MATERIALS AND METHODS 
Mice. Female 6-8-week-old C57BL/6, C57BL/6Tg (TcraTcrb)1100Mjb (OT-1), and C57BL/6-
IL12tm1Jm (IL-12p40 knockout), and perforin-deficient (C57BL/6-Prf1 /J)tm1Sdz , female mice 
purchased from Jackson Laboratories (Bar Harbor, ME) were maintained in micro-isolator cages 
and used for all experiments at 8-10 weeks of age. All experimental procedures were approved 
by our Institutional Animal Care and Use Committee.  
Cell lines, cell isolation and culture. MC38 adenocarcinoma was provided by Dr DL Bartlett, 
University of Pittsburgh (originally from Dr SA Rosenberg, NCI). EL4 and EG7 (OVA-
expressing EL4) cell lines were purchased from ATCC (Manassas, VA). Spleen CD4+ and CD8+ 
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T cells have been negatively selected using StemSepTM isolation columns (Stem Cell 
Technologies, Vancouver, BC) with 90-95% purity. In some in vitro experiments (Fig. 1b ), we 
performed additional anti-LyC6-mediated removal (89) of preactivated OT-1 cells or flow-sorted 
CD44-CD62L+ (naïve) and CD44+CD62L- (memory) cells. All cells were maintained in 
RPMI1640 with 10% heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA), glutamine, 
streptomycin and penicillin (Invitrogen). 
DCs. Bone marrow-derived DCs were generated in GM-CSF and IL-4 (both 1000 U/ml; 
Schering-Plough, Kenilworth, NJ)-supplemented cultures, as described (90). On day 6-7, 
CD11c+ DCs were isolated using anti-mouse CD11c-coated magnetic beads (Miltenyi Biotech.). 
DCs expressed CD11c, CD40, CD80, CD86, and MHC I and II ((90) and data not shown).  
Induction of IL-12p70. SEA (CD4+ and CD8+ T cell-activating superantigen (83, 91, 92); 
1ng/ml)-loaded DCs (2x104 cells/0.2 ml/well) were co-cultured for 48h with CD4+ Th cells (105 
cells/well), in the absence or presence of CD8+ T cells (105 cells/well). When indicated, 
(neutralizing) soluble (s)IFN-  receptor or (s)IL-4 receptor were added (10 µg/ml; R&D 
Systems). Alternatively, Ag-free, OVA257-264-, or SEA-loaded DCs were first cocultured for 48h 
with CD8+ T cells (0.75x105 or 3 x 105 cells; respectively from the spleens of OT-1- or wild-type 
mice), harvested, washed, counted, and stimulated (at 2x104 DCs/0.2 ml) with 5x104 CD40L-
transfected J558 cells (83, 93) for 24h. IL-12p70 concentrations were determined by ELISA 
(Endogen). 
In vitro DC killing. CD8+ T cells from wild-type or perforin-deficient mice were stimulated with 
SEA-loaded DC and IL-2 (20U/ml; Chiron Corp., Emeryville, CA) for 6 days. The resulting 
Granzyme Bhigh/CD62Llow (not shown) effector cells were co-incubated with DCs (3h; 5:1 ratio) 
in the presence or absence of SEA. Induction of apoptosis in CD11c+ DC was assessed by 
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staining for surface CD11c, followed by intracellular staining for active Caspase-3 (C92-605, BD 
Pharmingen).   
DC elimination in vivo. DCs (OVA257-264- or PBS-loaded; 1x106) were labeled with CSFE (1 
μM/L for 10 min at 37°C), washed 3 times and injected into the footpads. After 24h, single cell 
suspensions from popliteal lymph nodes were prepared and analyzed by flow cytometry. Total 
node cellularity was counted in hemocytometer.  
Induction of LCMV- or OVA-specific immune responses. LCMVgp33-41 peptide, 
(KAVYNFATC), the dominant H2-Db/Kb-restricted epitope of LCMV, and dominant H-2Kb-
restricted OVA epitope, OVA257-264 (SIINFEKL), were synthesized by the University of 
Pittsburgh Peptide Synthesis Facility. Peptide-loaded DCs were washed twice and injected s.c. 
(3x105 DCs in 0.2 ml of PBS) twice with 1-week interval. The presence of effector and memory 
CD8+ T cells in the spleens and lymph nodes of vaccinated animals was determined by 3-color 
flow cytometry after staining of isolated CD8+ T cells, with CD62L (MEL-14; BD-Pharmingen), 
Granzyme B (GB12l; CalTag), and tetramer (iTAgTM, Beckman-Coulter, Fullerton, CA). 
Tumor vaccines. DCs were loaded overnight with MC38 tumor cells lysates (three freeze-thaw 
cycles; centrifuged, and supernatant collected), at three tumor cell equivalents to one DC, in the 
presence of LPS. DCs were resuspended in RPMI 1640 and loaded, with OVA OVA257-264, 
LCMV gp33-41, or PBS. For preparation of the EG7 vaccine, DCs were loaded with OVA257-264 
(alone or with LCMVgp33-41). All vaccines were washed twice and suspended in PBS.  
Tumor therapy models. Wild-type C57BL/6 mice (7-12/group; including 2 animals/group for 
CTL assays), naïve or carrying week-1 or week-4 immune responses against LCMV or OVA, 
were inoculated (right flank; s.c.; day 0) with high numbers of tumor cells (3x105 MC38 or 3x106 
EG7), to induce rapid tumor growth that was only marginally sensitive to standard therapeutic 
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vaccines (see Fig. 3). The mice were vaccinated (3x105 DCs, on the distant site on same flank, 
s.c.) on day 3, or on days 5–9-11, as indicated). Tumors were measured by vernier calipers every 
3-4 days. Data are reported as the mean ± SEM of tumor area (product of the largest 
perpendicular diameters). 
CTL activity. 10 days after vaccination, splenocytes were harvested from two (tumor-bearing) 
mice per group. They were restimulated in vitro (1x106 cells/well) with 1x105 gamma-irradiated 
(10,000 R) MC38 or EG7 cells in the presence of 30 IU/ml rhuIL-2 in 24-well culture plates. 
Lymphocytes were harvested after 5 days and used in 5h 51Cr release assays against MC38 and 
EG7 targets, with EL4 cells used as non-specific controls.  
Statistical analysis. Data collected (day 4 till the last day of tumor measurement) were (natural) 
log transformed and used to fit a parametric mixed linear model that included animals as random 
effects with treatment group and day of measurement as fixed effects. If either group differences 
or group by time interaction were significant at p<.05 the analysis was applied to the last day of 
tumor area measurement. Data were (natural) log transformed when appropriate and a one way 
parametric analysis of variance (ANOVA) was used as an omnibus test of differences. Unless 
tests were significant at level α=.05, no further testing of specific contrasts was conducted. 






DC activating and DC-killing activities of resting versus effector CD8+ T cells 
In order to analyze the ability of mouse CD8+ T cells to affect DC functions in vitro, we used the 
previously-established models of the superantigen (SEA) (83, 91)-driven or chicken ovalbumin 
(OVA) (89, 94)-driven stimulation of T cells from wild-type C57BL/6 mice or TCR-transgenic 
(94) OT-1 mice, respectively. These models allowed us to promote the interaction of DCs with 
high numbers of CD8+ T cells without the need of prior T cell activation and clonal expansion. In 
accordance with our data showing that the superior ability of human CD8+ T cells to produce 
IFNγ at early stages of activation allows them to co-stimulate IL-12p70 production by DCs 
interacting with CD4+ T cells (83), freshly-isolated mouse CD8+ T cells strongly supported IL-
12p70 induction in co-cultures of SEA-loaded bone-marrow-derived DCs (90) with autologous 
CD4+ T cells (Fig. 2.1A). They also primed the SEA- or OVA257-264-loaded DCs for high IL-
12p70 production during subsequent interaction with CD40L-transfected J558 cells, used as 
CD4+ T cell surrogates (83, 93) (Fig. 2.1B). Similar to the human system, neutralization of IFNγ, 
but not IL-4 (another IL-12-enhancing cytokine (92, 95)), abolished the IL-12-enhancing activity 
of CD8+ T cells (Fig. 2.1A). As expected (83), not only the simultaneous interaction of DCs with 
CD8+ T cells and CD4+ T cells (Fig. 2.1A), but also their sequential interaction with CD8+ T 
cells followed by CD40L stimulation (Fig. 2.1B) resulted in the augmented IL-12p70 
production, with naïve and memory CD8+ T cells being similarly effective (Fig.2.1B-top, inset). 
These data verified that, similar to human CD8+ T cells, mouse CD8+ T cells can act as “helper” 








Figure  2.1 DC-activating function of resting CD8+ T cells.  
A, CD8+ T cells support IL-12p70 induction in DC-CD4+ T cell co-cultures. SEA-coated (83, 91) DCs (90) were co-
incubated with syngeneic CD4+T cells, in the absence or in the presence of (IFNγ-producing, not shown) spleen-
isolated CD8+ T cells. Soluble IL-4R or IFNγR were used selectively neutralize IL-4 or IFNγ , two cytokines with 
IL-12-enhancing activities (83, 92, 95). Data (mean ± SD) from one experiment of three that yielded similar results. 
B, Interaction with CD8+ T cells primes DCs for high IL-12p70 production. (top) DCs were cocultured for 48h with 
CD8+ T cells from wild-type B6 mice either in the absence or presence of SEA, prior to washing and stimulation 
with CD40L (83, 93). Addition of SEA alone (no T cells) had no or marginal effect ((83) and data not shown). The 
inset: equivalent effectiveness of naïve and memory CD8+ T cells. (bottom) DCs were cocultured with H-2Kb–
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restricted OVA257–264 -specific CD8
+ T cells, freshly isolated from spleens of OT-1 mice, in the presence of OVA257–
264 peptide, prior to washing and CD40L stimulation. 
 
In contrast to resting T cells, six-day preactivated effector CD8+ T cells, efficiently killed 
Ag-carrying DCs (Fig. 2.2). In accordance with the in vivo-demonstrated key role of perforin in 
CTL-dependent DC elimination (37), CD8+ T cells from perforin-deficient mice were defective 
in their ability to kill DCs (Fig. 2.2).  
 
Figure  2.2 Effector T cells kill DCs in vitro.  
SEA-loaded DC were co-cultured with pre-activated (Granzyme Bhigh/CD62Llow; data not shown) effector CD8+ T 
cells from wild-type or perforin-deficient mice. Similar results were obtained in one additional experiment. 
 
Taken together, these data verified that CD8+ T cells can act both as activators and as 
killers of Ag-carrying DCs, but indicated that these two functions are performed at different 
stages of CD8+ T cell activation. They suggested that non-cytotoxic naive or memory CD8+ T 
cells versus the effector cells with CTL function may play opposite functions regulating the 
course of immune responses. In order to establish an in vivo model that would allow us to test in 
wild-type mice the regulatory impact of either the cytotoxic (effector) or non-cytotoxic 
(memory) CD8+ T cells, we pre-immunized wild-type C57BL/6 mice with OVA257-264 for 1 or 4 
weeks. As expected, in 1 week-immunized animals we observed high numbers of tetramer-
positive CD8+ T cells with CD62Llow/Granzyme Bhigh effector phenotype. In sharp contrast, 
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CD8+ T cells that were obtained 4 weeks after immunization demonstrated a selective presence 












Figure  2.3 Predominance of OVA257-264/H-2K
b-specific effector (1wk) versus memory T cells (4 wk). 
 Note the predominance of tetramer-positive Granzyme B+/CD62L- effector cells in 1 week-immunized mice, as 
opposed to selective presence of Granzyme B-/CD62L+ memory cells in the spleens of 4 week immunized mice (n = 
3 mice per group; see the bottom for representative data from individual animals). The frequencies of tetramer-
positive CD8+ T cells in 1 week- and 4 week-immunized mice were 4.3% (+/- 1.5) and 0.7% (+/-0.3), respectively. 
Data from one of two experiments that yielded similar results. Inset: Selective elimination of OVA257-264-carrying 
CFSE-labeled DCs in 1-week-immunized, but not 4 week-immunized, mice. Naïve mice and 1-week-preimmunized 
mice receiving sham-loaded DCs served as control groups. Mice (3 mice/group) were injected with 106 DC and 
draining lymph nodes (37, 80) were removed after 16h. 
 
Similar to previous reports (37, 80, 85), we observed that the animals harboring 
CD62Llow/Granzyme Bhigh effector CD8+ T cells, induced by pre-immunization with OVA257-264 
one week earlier, rapidly eliminated Ag-loaded DCs (Fig. 2.3, inset), while OVA-loaded DCs 
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could be readily recovered from the vaccine-draining lymph nodes of naïve mice or mice 
harboring 4 week old memory-type CD62Lhigh/Granzyme Blow T cell responses.  
 
Memory CD8+ T cells support the DC-mediated induction of tumor-specific CTL responses 
 
 In order to test the possibility that Ag-specific CD8+ T cells at different stages of activation 
indeed play different regulatory roles, we have used a model of therapeutic vaccination with 
tumor-loaded DCs carrying additional, tumor-unrelated, MHC class I-restricted epitopes of 
OVA257-264 or Lymphocytic Choriomeningitis Virus (LCMV) glycoprotein (LCMVgp33-41) (Figs. 
2.4 and 2.5). We analyzed the impact of including tumor-unrelated “heterologous” class I-
restricted peptide epitopes into DC-based vaccines (tumor-loaded DCs) upon the induction of 
CTL responses and the therapeutic activity of vaccination against established tumors (Fig. 2.4A). 
In such models, the “heterologous” helper epitopes were only present in cancer vaccines and 
were not expressed by the tumor itself. Therefore, any “helper” or “suppressor” impact of 
(OVA257-264-specific or LCMVgp33-41-specific) CD8
+ T cells on the development of the immune 
responses against MC38 or EG7 tumors, could be analyzed in isolation from a possible indirect 
modulatory impact of CD8+ T cells, mediated by tumor antigens and other tumor-derived factors 
differentially released from the CTL-targeted tumor tissues. 
In order to model a clinically-relevant situation where significant numbers of resting T 
cells can be employed to interact with cancer vaccine in wild-type animals, we have used wild-
type C57BL/6 mice harboring memory-type CD8+ T cells against defined MHC class I-restricted 
epitopes of OVA or LCMV. For the same purpose, we have administered the vaccines to the 
animals bearing day 3-5 established tumors, the time point where, in analogy to the clinically-
 28 
applied therapeutic cancer vaccines (37, 80), standard vaccinations with tumor-loaded DCs were 
only marginally effective.  
As shown in Figure 2.4B, the inclusion of OVA257-264 epitope in cancer vaccines 
composed of autologous DCs loaded with the relatively poorly immunogenic MC38 tumor lysate 
supported the generation of MC38-specific CTL responses in wild-type C57BL/6 animals. 
Similar data was also obtained in a model of wild-type mice harboring memory responses against 
LCMVgp33-41, a dominant epitope of a natural mouse pathogen, where the inclusion of 
LCMVgp33-41 peptide as a “heterologous helper epitope” strongly enhanced the induction of 
CTLs against established MC38 tumors (Fig. 2.4B).  
The vaccines including the LCMVgp33-41 “CD8 helper” epitope not only showed 
strongly-elevated CTL-inducing function against the poorly-immunogenic MC38 
adenocarcinoma, but also further enhanced the CTL responses against the highly-immunogenic 
(OVA-expressing) EG7 lymphoma, induced by OVA257-264-loaded DCs (Fig. 2.4D). The ability 
of the CD8+ T cells specific for the same individual epitope (OVA257-264), to both provide “CD8 
helper” signals (Fig. 2.4B) and to benefit from such signals (Fig. 2.4D) indicates that CD8+ T 
cell help is not restricted to responses against some unique antigens (e.g. responses to “strong” 
immunogens facilitating the responses to “weak” immunogens), but that any naïve CD8+ T cells 
that can first receive the CD8 help and later, after becoming memory cells themselves, can 






























Figure  2.4 Memory CD8+ T cells support the DC-mediated induction of tumor-specific CTL responses.  
A, Schema of the experimental protocol. B, OVA257–264-specific CD8+ T cells support the induction of CTLs specific 
for MC38 adenocarcinoma. Mice carrying memory-type OVA257–264-specific CD8+ T cell responses, and inoculated 
with MC38 tumor (day 0), were treated (s.c.; day 3) with DCs loaded with MC38 lysate alone or with OVA257–264 as 
tumor-unrelated “heterologous” helper epitope. Left: Induction of CTL activity in the spleens of the differentially-
treated mice. Right: Comparison of CTL activity of the splenocytes from the DCs/MC38 lysate/LCMVgp33-41-
treated mice against the vaccine-relevant (MC38) and irrelevant (EL4) targets. Data from one of two experiments 
that yielded similar results. C, Memory-type LCMVgp33-specific CD8+ T cells support the induction of MC38 
adenocarcinoma-specific CTLs. Tumor-bearing mice with memory-type LCMVgp33-41-specific CD8+ T cell 
responses were injected (s.c.) with DCs loaded with MC38 tumor lysate, alone or with LCMVgp33-41 as a 
“heterologous” helper epitope. The data from one of three independent experiments that all yielded similar results. 
D, LCMV-specific CD8+ T cells support the induction of CTLs against OVA257–264-expressing EG7 lymphoma. 
Tumor-bearing mice with memory-type LCMVgp33-specific CD8+ T cell responses were injected (s.c.) with DCs 
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loaded with OVA257–264 peptide, as the EG7 tumor-relevant antigen, either alone or with the LCMVgp33-41 peptide, as 
a tumor-unrelated “heterologous” helper epitope. Similar results were obtained in an additional experiment.  
 
Heterologous CD8+ T cell help supports the therapeutic effects of cancer vaccines 
In order to test whether “helper” signals from memory CD8+ T cells can enhance the therapeutic 
activity of vaccination against established tumors, we compared the therapeutic activity of the 
DCs loaded with tumor-relevant antigens, alone or with LCMVgp33-41 peptide, as therapeutic 
vaccines against the established (day 3-5) MC38 and EG7 tumors in wild-type C57BL/6 mice, 
either naïve or carrying memory-type LCMV-specific CD8+ T cells. As shown in Figure 2.5A, 
in such therapeutic settings, DCs loaded with tumor material alone had only marginal impact on 
the growth of established MC38 tumors. In LCMV-naïve mice, this outcome of was not 
improved by the inclusion of the LCMVgp33-41 “helper” epitope in the vaccines (Fig. 2.5A, left). 
However, in mice harboring memory-type responses against the MHC class I-restricted 
LCMVgp33-41 epitope, the vaccination with DCs loaded with MC38 tumor lysate and LCMVgp33-
41, the “heterologous CD8 helper” peptide, resulted in a distinct therapeutic effect against day 5 
established tumors that were resistant to treatment with standard DC-based vaccines (Fig. 2.5A: 
right). These beneficial effects of “heterologous CD8 help” could not be mimicked by the 
vaccination with DCs loaded with LCMVgp33-41 alone, demonstrating that the reduction in tumor 
growth is not due to nonspecific immunostimulatory effects of activation of high numbers of 
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Figure  2.5 Heterologous CD8+ T cells support the therapeutic activity of cancer vaccines.  
A, Memory-type LCMVgp33-41-specific CD8+  T cells promote therapeutic effects of vaccination against day 5 
established MC38 tumors. MC38-bearing C57BL/6 mice (n=5 mice/group), either naive (left) or carrying memory-
type (week 4) LCMVgp33-41-specific CD8+ T cell responses (right) were inoculated with MC38 tumors at day 0 and 
were treated on day 5, day 9, and day 11 after tumor inoculation. B-D, Day 3 tumor-bearing mice (B: n=10 per 
group; C-D: n=5 per group) with memory-type responses against tumor-unrelated “heterologous” helper antigens 
were injected (s.c.) with: PBS as a negative control (open squares), with DCs loaded with tumor antigen alone 
(MC38 tumor lysate or OVA257–264 in the EG7 model), or with the relevant tumor antigen plus a tumor-irrelevant 
“heterologous” helper epitope (closed circles). B, Memory-type LCMVgp33-41-specific CD8+ T cells support the 
therapeutic activity of vaccination against MC38 adenocarcinoma. C, Memory-type OVA257–264-specific CD8+ T 
cells support the therapeutic activity of vaccination against MC38 adenocarcinoma. D, Memory-type LCMVgp33-41-
specific CD8+ T cells support the therapeutic activity of vaccination against OVA257–264-expressing EG7 lymphoma. 
Data (mean ± SEM) from one of two separate experiments in each model. The differences between the treatment 
groups were evaluated using ANOVA: NS: no statistically-significant differences (p>.05). 
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Similar enhancement of the therapeutic efficacy of vaccination has been observed in three 
additional models, when using LCMVgp33-41 or OVA257-264 to enhance the antitumor effects of a 
single (rather than triple) dose of vaccine against the 3 day old MC38 tumors (Fig. 2.5 B, C), or 
when using LCMVgp33-41 to boost the antitumor effects of vaccination against significantly more 
immunogenic EG7 lymphoma (Fig. 2.5D). In accordance with the data on the induction of 
tumor-specific CTLs (Fig. 2.4), the results of these functional tests of anti-tumor activity 
demonstrated that OVA257-264-specific CD8
+ T cells at their naïve stage can benefit from “helper” 
signals delivered by memory T cells (in the current experiments: specific for LCMVgp33-41), but 
at the memory stage they can themselves act as a source of CD8+ T cell helper signals, verifying 
that the ability to receive and provide “CD8 helper” signals is a general feature of CD8+ T cells.  
 
Critical role of DCs in mediating “CD8 help” 
While the inclusion of LCMVgp33-41 (or OVA257-264) peptides strongly enhanced the 
immunologic and antitumor effects of vaccination in the animals harboring “memory-type” 
CD8+ T cells specific for such “heterologous helper epitopes” (Fig. 2.6), in accordance with the 
DC-killing activity of effector CD8+ T cells (37, 80, 86), these positive effects were eliminated in 
the animals pre-immunized with LCMV at 1 week prior to tumor inoculation (Fig. 2.6A). In 
further support of the central role of DCs and the DC-produced cytokines, the “heterologous 
help” from memory-type CD8+ T cells could not be mediated by IL-12/IL-23-deficient DCs 
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Figure  2.6  Critical role of DCs in mediating CD8 help for anti-cancer immunity.  
A, Effector CD8+ T cells do not deliver “heterologous CD8 help”. Three days after MC38 tumor inoculation, 
C57BL/6 mice (n=5) with 1 week-old LCMV-specific responses received a single s.c. injection of MC38 tumor 
lysate with or without LCMVgp33-41 peptide loaded on DCs from wild-type mice and monitored for the kinetics of 
tumor growth. B, IL-12p40-deficient DCs (unable to produce IL-12p70 and IL-23) do not mediate heterologous 
CD8 help. Three days after MC38 tumor inoculation, wild-type C57BL/6 mice (n=5) with 4 week-old LCMV-
specific CD8+ T cell responses were treated with the indicated vaccines. Mice received single s.c. injections of DCs 
(generated from wild-type or IL-12p40-knockout mice) loaded with MC38 tumor lysate alone or with LCMVgp33-41 









The current data demonstrate that, in contrast to effector CD8+ T cells that kill DCs and suppress 
Ag-specific immune responses (36, 37, 80, 85, 86), memory CD8+ T cells can act as de facto 
“helper cells”, supporting the DC-mediated immunologic and anti-tumor effects of cancer 
vaccines.  
Our observations that OVA257-264-specific CD8
+ T cell responses can both benefit from 
the “helper signals” delivered by memory cells (e.g. from LCMV-specific CD8+ T cells) and can 
provide such signals, directly demonstrate that CD8+ T cells of a single specificity can first 
benefit from the help delivered by memory T cells and, once expanded and having reached 
memory stage, they can themselves act as helper cells. The ability of memory CD8+ T cells to 
support the DC-mediated activation of additional naïve CD8+ T cells suggests that the 
phenomenon of immune memory, in addition to qualitative changes in the activation 
requirements of memory cells (72-75), may also involve a different pattern of interaction of 
CD8+ T cells with Ag-carrying DCs.  
Our findings help to explain the requirement for a delayed administration of booster 
doses of preventive vaccines to achieve the optimal expansion of pathogen-specific CD8+ T cells 
and the optimal vaccine effectiveness (76, 77). Interestingly, recent evidence indicate that 
priming performed under non-inflammatory conditions allows for effective administration of 
booster vaccines substantially sooner than when priming with live pathogen (76). However, it 
remains to be tested whether such non-inflammatory priming conditions result in impaired 
induction of the effector (and thus suppressive) functions of the pathogen-specific CD8+ T cells.  
The existence of distinct “suppressor” and “helper” stages of CD8+ T cell activation may 
help to explain the generally poor efficacy of therapeutic vaccinations of cancer-bearing patients 
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that show predominance of terminally-differentiated effector cells (96-98). It also helps to 
explain the high efficacy of prime-boosting vaccination strategies (75), when the first and second 
doses of vaccine are delivered using antigenically-distinct vectors.  
The mechanism of helper function of memory CD8+ T cells in the settings of established 
cancer is a subject of our current follow-up analyses. While our data demonstrate the key role of 
Ag-carrying DCs in this respect, it is unclear whether the “heterologous” memory CD8+ T cells 
just hyper-activate DCs, allowing them to provide immunostimulatory signals to naïve/resting 
tumor-specific CD8+ T cells prior to their destruction by effector cells, or whether memory CD8+ 
T cells can also protect Ag-carrying DCs from CTL killing. It has been recently proposed that 
the CD4+ T cell help for CTL responses is essential mainly for the secondary expansion of CD8+ 
T cells, rather than for their effective priming (77). These observations raise the possibility that 
the protection of DCs from CTL killing (86, 99) may be as important as the originally proposed 
DC activation or “licensing” (100-102) in the overall mechanism of the CD4+ T cell help.  
The current data directly implicate the possibility of enhancing the effectiveness of 
therapeutic vaccination of cancer patients by incorporating tumor-unrelated “heterologous” 
epitopes that promote the interaction of the vaccine-carrying APCs with naturally occurring or 
artificially-induced memory-type T cells. While in the current studies, we have either used (in 
vitro) high numbers of resting CD8+ T cells from TCR-transgenic animals, or have involved (in 
vivo) the memory CD8+ T cells induced by a pre-immunization of wild type-animals, the most 
obvious source of “heterologous CD8 help” in cancer patients are the memory-type CD8+ T cells 
induced naturally by past infections or by prior vaccinations against “childhood diseases” or such 
pathogens as influenza or hepatitis.  
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Our data showing that the helper functions are a selective feature of memory CD8+ T 
cells, but not effector cells, indicate the existence of a novel mechanism contributing to the 
phenomenon of CD8+ T cell memory. Our observations help to explain the benefits of delayed 
application of booster doses of preventive vaccines and high efficacy of prime-boost vaccination 
strategies, facilitating the development of effective strategies of therapeutic vaccination of 
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3 MEMORY CD8+ T CELLS PROTECT DENDRITIC CELLS FROM CTL 
KILLING 
3.1 ABSTRACT 
CD8+ T cells have been shown capable of either suppressing or promoting immune responses. In 
order to reconcile these contrasting regulatory functions, we compared the ability of human 
effector and memory CD8+ T cells to regulate survival and functions of dendritic cells (DC). We 
report that, in sharp contrast to the effector cells (CTLs) that kill DCs in a Granzyme B- and 
perforin-dependent mechanism, memory CD8+ T cells enhance the ability of DC to produce IL-
12 and to induce functional Th1- and CTL responses in naïve CD4+ and CD8+ T cell populations. 
Moreover, memory CD8+ T cells, that release the DC-activating factor TNFα prior to the release 
of cytotoxic granules, induce DC expression of an endogenous Granzyme B inhibitor PI-9 and 
protect DC from CTL killing with similar efficacy as CD4+ T helper cells.  The currently 
identified DC-protective function of memory CD8+ T cells helps to explain the phenomenon of 
CD8+ T cell memory, reduced dependence of recall responses on CD4+ T cell help, and the 




In addition to their function as cytotoxic T cells (CTLs) capable of killing transformed or 
infected cells in a perforin- and FasL-dependent mechanism (2, 103), CD8+ T cells have also 
been shown to play a regulatory role, being able to suppress Ag-specific immune responses (79, 
104). Their suppressor activity (32, 105, 106) involves the elimination of antigen-carrying DCs 
by effector CD8+ T cells (80) in a perforin-dependent mechanism (37). Activated CD8+ T cells 
have been shown to limit the CTL responses by restricting DC survival and the duration of 
antigen display in vivo in mice infected with Listeria, LCMV, HSV, and malaria (35, 36, 99).  
This self-limiting nature of CD8+ T cell responses can be counteracted by CD4+ T helper cells 
(86, 99), known to be important for the establishment of CD8+ T cell memory and effective 
expansion of CTL precursors during recall responses (77, 107, 108).  While the mechanism of 
helper activity of CD4+ T cells was originally considered to involve Th cell-produced IL-2 (109) 
and the CD40L-mediated elevation of the stimulatory capacity of DCs (100-102), it was 
subsequently demonstrated that CD40L-expressing CD4+ T cells can induce in DCs endogenous 
Granzyme B inhibitor (serpin SPI-6/PI-9) (86),  rescuing the Ag-carrying DCs from killing by 
the same CTLs that they induce, and thus prolonging the time-frame of effective stimulation of 
the expanding population of Ag-specific CD8+ T cells (86, 99). In contrast to the widely-studied 
suppressive activity of CD8+ T cells, only recently it was demonstrated that CD8+ T cells can also 
activate DCs and promote the Th1- and CTL-mediated type-1 immunity (82-84, 87, 110, 111).  
In order to reconcile the paradoxical ability of CD8+ T cells to act as both suppressor and 
helper cells, we addressed the possibility that helper and suppressor functions are selectively 
displayed by CD8+ T cells at different stages of activation. Using the models of peptide-specific- 
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and superantigen-driven activation of CD8+ T cells isolated from blood and tissues and the in 
vitro pre-activated CD8+ T cells at different stages of activation, we show that the DC killing and 
DC-activating/protecting functions are exerted sequentially by human CD8+ T cells: While 
effector CD8+ T cells kill DCs in a Granzyme B- and perforin-dependent pathway, TNFα-
producing memory CD8+ T cells display an equivalent activity to CD4+ Th cells in protecting 
DCs from premature elimination by the effector cells, supporting the induction of functional Th1 
and CTL responses.  
3.3 MATERIALS AND METHODS 
Media, reagents, and cell lines. The cell cultures were performed using either IMDM 
(Invitrogen, Carlsbad, CA) supplemented with 10% FBS (Hyclone, Logan UT) or serum-free 
AIM-V medium (Invitrogen). rhuGM-CSF and IL-4 were gifts from Schering Plough 
(Kenilworth, NJ). IL-2 was kindly provided by Chiron Corporation (Emeryville, CA). IFNγ, 
TNFα, and IL-1β were purchased from Strathman Biotech (Germany). Staphylococcus 
Enterotoxin B (SEB), used for priming high number of naïve CD8+ T cells (83, 91), was 
obtained from Toxin Technologies (Sarasota, FL). CD40L-transfected J588 plasmacytoma cells 
were a gift from Dr. P Lane (University of Birmingham, UK) and JY-1 cells were a gift from Dr. 
Eddy Wierenga (University of Amsterdam). Granzyme B inhibitors IETD-CHO and Z-IETD-
fmk were obtained from Calbiochem (San Diego, CA). 
Isolation of the naïve, memory and effector T cell subsets from peripheral blood and 
tissues. Mononuclear cells, obtained from the peripheral blood of healthy donors, were isolated 
by density gradient separation using Lymphocyte Separation Medium (Cellgro Mediatech, 
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Hendon VA). Naïve CD4+CD45RA+T cells and naïve CD8+CD45RA+T cells were isolated by 
negative selection with the StemSep CD4 and CD8 enrichment cocktails, respectively (StemCell 
Technologies Inc, Vancouver, Canada). Biotinylated anti-CD45RO antibody was used in 
combination with enrichment cocktails for isolation of naïve population. The phenotype of naïve 
CD8+ CD45RA+CCR7+  T cell population was confirmed by flow cytometry (Supplementary 
Figure 1).Tissue-type effector CD8+ T cells were obtained from colorectal cancer patients, 
undergoing surgical resection of liver metastasis, and cultured overnight in low dose IL-2 to 
recover from the isolation-induced stress and possible effects of tumor derived factors 
(Supplementary Figure S1: Appendix A). The memory subset CD8+CD45RA-CCR7+ T cells 
from peripheral blood (see Supplementary Figure S1: Appendix A) was isolated using 
CD45RA-depleting/CD8 enrichment cocktail (StemCell Technologies). 
Generation of dendritic cells. Day 6 immature DCs (used as a readout of functional activity of 
CD8+ T cells), were generated from peripheral blood monocytes cultured (5x105 per ml) in 
IMDM/10%FBS supplemented with rhuIL-4 and rhuGM-CSF (both at 1000U/ml) in 24 well 
plates (Falcon, Becton Dickinson Labware, NJ).  Type-1 polarized mature DCs, used for the 
generation effector- and memory-type CD8+ T cells in vitro, were obtained in serum-free AIM-V 
medium with IL-4 and GM-CSF, and matured (days 6-8) in the presence of  TNFα, IFNγ,IL-1β, 
IFNα, and poly I:C,  as described (112). 
In vitro induction of effector- and memory-type CD8+ T cells. Naïve CD8+CD45RA+CCR7high 
(see Supplementary Fig. S1: Appendix A) T cells (5x105 cells/well) were activated with SEB 
pulsed DCs (5x104 cells/well) in the presence of sCD40L (Alexis Corporation, San Diego, CA).  
Although CD8+CD45RA+ T cells may contain low frequencies of primed cells, our previous 
studies showed lack of differences between such cells isolated from adult or cord blood, when 
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using polyclonal models of activation (83). IL-2 (50U/ml) and IL-7 (5ng/ml) were added on day 
3. Subsequently culture medium was replenished with fresh medium and cytokines every two 
days. Priming for 8 days resulted in CD8+ T cells with high content of the cytotoxic granule 
components Granzyme B and perforin, referred to effector-type CD8+ T cells in the current 
study. CD8+ T cells primed and cultured for 15 days yielded a functional phenotype of memory 
cells with low Granzyme B and perforin content. The HLA-A2 restricted CD8+ T cell clone (83) 
recognizing melanoma antigen gp100 (209-217) was cloned from TIL 1520 cell line provided by 
Drs Steven Rosenberg and John Wunderlich (National Cancer Institute, Bethesda, MD), and 
used either four days after Ag-specific restimulation, or after prolonged culture (> 4 weeks) in 
IL-2 (100U/ml), in the absence of stimulation. 
Modulation of DC function by CD8+ T cells. CD8+ T cells (5×104 cells) were added to day 6 
immature DC cultures with or without antigen SEB (or gp100 peptide). After 48 hours cells were 
harvested, washed and analyzed by flow cytometry or stimulated with CD40L transfected J588 
cells (83) for 24 hours. For DC protection studies, memory-type CD8+ T cells (5×104 cells/ml) 
were added to immature DC culture 6-8 hours prior to the addition of effector-type CD8+ T 
cells(5×104 cells/ml). When indicated, day 8 primed CD8+ T cells were pretreated with the 
perforin inhibitor (83) Concanamycin A (CMA: 100 nM) for 2 hours and then added to immature 
DC culture. The survival of DCs was assessed by staining with nonyl acridine orange dye (NAO; 
Sigma), as a marker of apoptosis (loss of mitochondrial potential: NAO which binds to 
mitochondrial cardiolipin in membrane potential dependent manner) (113). Light scatter 
properties and Annexin V staining have been used, yielding similar results (see Fig. 3.3 and 
Supplementary Fig. S 3b). Briefly, DCs were stained with 0.2μM NAO in culture medium for 
15 minutes at 370C. The cells were washed and immediately analyzed by flow cytometry. For 
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blocking TNFα release in day 14 memory type CD8+ T cells, recombinant human soluble TNF 
RI (R&D Systems) and anti-human TNFα antibody Infliximab (a gift from Dr. Catharien 
Hilkens, NewCastle, UK) were added to culture wells with DCs and day 14 memory-type CD8+ 
T cells. 
Flow cytometry. Cell surface phenotype was analyzed by flow cytometry using Beckman 
Coulter XL. The FITC and PE-labeled isotype controls (mouse IgG1 and IgG2a), anti-human 
CD86, anti-human perforin were obtained from BD Pharmingen. CD83 monoclonal antibody 
was purchased from Immunotech and PE-labeled Granzyme B antibody was obtained from Cell 
Sciences. Goat anti-mouse IgG- FITC conjugated was obtained from Caltag Laboratories. For 
detection of intracellular PI-9, we used PI-9 specific mouse monoclonal IgG1 antibody as 
described (114). Briefly, for intracellular staining of PI-9, dendritic cells were washed and then 
blocked with human Ig for 10 minutes at room temperature. Subsequently, cells were 
permeabilized with 300μl of Permiflow (Invirion, Frankfort, MI) for 60 minutes at room 
temperature and then washed. The cells were stained with unconjugated anti human PI-9 
antibody for 20 minutes at room temperature followed by staining with FITC conjugated goat 
anti-mouse IgG antibody. Granzyme B and perforin staining were performed according to 
manufacturer’s protocol, using Permiflow as permeabilization reagent. 
Cytokine detection. Concentrations of IL-12, TNFα, IL-5, and IFNγ were determined using 
specific ELISA, using matched antibody pairs from Endogen. Granzyme B was detected in the 
supernatants by ELISA (Diaclone, Besancon, France). 
Microscopy. For TNFα, Granzyme B, and PI-9 visualization experiments, DCs were cultured on 
collagen coated cover glass (size 12RD, thinness 1, Propper Manufacturing Co., NY) placed in 
24 well plates (Falcon). Before imaging, CD8+ T cells, labeled with either CFSE (2.5μM) or 
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Calcein blue AM (10μM) (Molecular Probes) according to manufacturer’s protocol, were added 
to SEB pulsed DCs (day 6) and incubated for 2 hours at 37o C to allow conjugate formation. 
Following incubation, cells were fixed with 2% paraformaldehyde, permeabilized with Triton X, 
and were blocked with normal goat serum (Sigma). The primary antibodies were mouse anti-
human granzyme B (Caltag), rat anti- human TNFα (Serotec), mouse anti-human CD11c – Cy5 
(BD Pharmingen), and mouse anti-human PI-9. The secondary antibodies were goat anti-mouse 
Cy3 Fab 1 fragment and goat anti-rat Cy3 (Jackson ImmunoResearch). All the antibodies were 
used at final concentration of 5μg/ml. Fixed and stained DC-CD8 conjugates were imaged with 
BX51 upright epifluorescence microscope (Olympus) with a 60X objective and image capture 
was performed using Magnafire software (Optoronix). For PI-9 localization, DC-CD8 conjugates 
were imaged with Olympus 500 Scanning Confocal Microscope (Olympus) with 60X objective 











CD8+ T cells at different stages of activation selectively kill or activate DC. 
In order to evaluate the DC-modulating functions of freshly-isolated effector and memory CD8+ 
T cell subsets and in vitro differentiated naïve CD8+ T cells at different stages of activation, we 
have used a superantigen (SEB) model (83, 115, 116). Similar to TCR transgenic mice, this 
model allows the activation of a high proportion of CD8+ T cells (83, 91) without the need for 
prior cloning. In accordance with the observations from the in vivo TCR transgenic mouse 
models (37, 99), we observed that tissue-isolated effector CD8+ T cells (but not memory or naïve 
CD8+ T cells) rapidly killed immature DCs (Fig. 3.1A: left, also see Supplementary Figs. S1 
and S2: Appendix A). In sharp contrast, blood-isolated memory CD8+ T cells did not kill DCs 
(Fig 3.1A: right), but instead activated the DC, increasing their expression of the maturation-
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Figure  3.1 DC-killing versus DC-activating function of tissue–isolated effector and blood-isolated memory 
CD8+ T cells. 
(A-B) Tissue-isolated effector CD8+ T cells kill DCs while blood-isolated memory CD8+ T cells induce DC 
maturation and prime them for high IL-12p70 production. SEB pulsed immature DCs (day 6) were co-incubated 
with blood-derived memory CD8+ T cells or tissue-derived effector CD8+ T cells for 48 hours. (A) DC viability was 
assessed by staining with NAO (113). Left: tissue-derived effector CD8+ T cells eliminate DCs, as indicated by 
decrease in NAO staining intensity, demonstrating the loss of mitochondrial integrity. Right: blood-isolated memory 
CD8+ T cells do not kill DCs as reflected by the maintained NAO staining pattern of the DCs. (B) Left: DC 
activation status was determined by flow cytometric analysis for surface expression of the co-stimulatory molecule 
CD86 and DC maturation associated marker CD83. Right: IL-12p70 production by DCs following stimulation with 
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J588-CD40L, as measured by ELISA. Results (mean +/- SD or triplicate cultures) are representative of three 
independent experiments. 
 
Similar to the IFNγ-dependent ability of naïve CD8+ T cells to elevate the IL-12 
production in DCs (83), but in contrast to the effector cells, memory CD8+ T cells primed DCs 
for high production of IL-12p70 upon subsequent stimulation with CD40L (Fig. 3.1B: right).  
In order to verify that such reciprocal DC-modulating activities of tissue-isolated 
effector- and blood-isolated memory CD8+ T cells indeed reflect their different stages of 
differentiation, we have used a SEB-based model of priming of blood-isolated CD8+CD45RA+ T 
cells (83), allowing us to study the regulatory functions of the same CD8+ T cell cultures at 
different time points after activation. As shown in Figure 3.2A (left, see the insets), similar to 
mouse in vivo models of CD8+ T cell differentiation (117), CD8+ T cells expanded for 6-8 days 
acquired a Granzyme Bhigh, perforinhigh phenotype, typical of cytotoxic effector cells, and 
acquired the ability to kill SEB-loaded tumor cells (Supplementary Fig. S 3a: Appendix A). 
Similar to the tissue-isolated effector cells, such in vitro activated day 6-8 (effector-type) CD8+ T 
cells effectively killed DC, as assessed by NAO staining (Fig. 3.2A: left) or Annexin V (See 
Supplementary Fig. S 3b: Appendix A).  
Compared to the effector-type CD8+ T cells, the cells activated for more than 14 days 
(memory-type) expressed reduced levels of Granzyme B and perforin. In contrast to the effector 
cells, such memory-type CD8+ T cells no longer killed DCs (Fig. 3.2A: right). Instead, similar to 
the blood-circulating memory cells, memory-type CD8+ T cells induced DC maturation 
(manifested by up-regulation of CD86 and CD83) and primed DCs for high production of IL-





GRANZYME B (T) GRANZYME B (T)
PERFORIN (T)
In vitro generated effector-type
CD8+ T cells with DCs
In vitro generated memory-type
CD8+ T cells with DCs

















Recently-activated gp100- specific  
CD8+ T cells with DCs
Resting gp100-specific  




















































Figure  3.2 DC-killing versus DC-activating functions of in vitro generated effector-type CD8+ T cells and 
memory-type CD8+ T cells at different stages of activation. 
Interaction of DCs with the in vitro generated effector (left)- or memory (right)-type CD8+ T cells (A, C) or with 
melanoma (gp100)-specific CD8+ T cells (B, D), at early or late stages of activation.  (A, B): Left: in vitro generated 
Granzyme Bhi/ perforinhi effector-type CD8+ T cells and activated gp100 specific CD8+ T cells kill DCs as evident 
from decrease in NAO staining intensity. Right: in vitro generated Granzyme Blo/ perforinlo memory-type CD8+ T 
cells and resting gp100-specific CD8+ T cells do not kill immature DCs as reflected by the maintained NAO staining 
pattern of the DCs. (C, D):  Memory-type CD8+ T cells at later stage of activation and resting melanoma (gp100) 
specific CD8+ T cells induce DC maturation and prime DC for enhanced IL-12 production. Day 6, immature HLA-
A2+ DCs were co-cultured with melanoma gp100-specific HLA-A2 restricted CD8+ T cells, in the presence of 
gp100(209-217) peptide (shaded histograms). Memory-type CD8+ T cells were co-cultured with SEB loaded DCs for 
48 hours.  Left: Activation status of DCs (CD86, CD83) was assessed by flow cytometry. Right: IL-12p70 was 
measured in supernatants after stimulation of DCs with J588-CD40L. In contrast to the presence of live activated 
DC in cultures containing memory-type T cells, all DCs were rapidly eliminated from the cultures containing 
effector cells. Results are representative of three independent experiments. DC killing and DC activation required 
the presence of antigen in all the above systems (not shown). 
Similar, stage of activation-dependent, differences were observed in case of CD8+ T cells 
activated with a HLA-A2-restricted peptide antigen, gp100(209-217). As shown in Figures 3.2B 
and 3.2D, human gp100-specific CD8+ T cell clone rapidly killed immature DCs when being 
pre-activated with Ag-loaded DCs for four days, but lost such DC-killing function following 
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their prolonged culture in the absence of antigen. Similar to the blood-isolated memory CD8+ T 
cells and day 14 SEB-activated memory-type cells, such “resting” clonal gp100 CD8+ T cells 
efficiently induced DC maturation and primed DCs for high IL-12 production (Fig. 3.2D).  
The inability of the memory-type CD8+ T cells to kill DCs did not result from any 
intrinsic defect resulting from long-term cultures, since they regained the ability to kill DCs upon 
short-term restimulation (Supplementary Fig. S 3c: Appendix A). These data, in conjunction 
with the results obtained using blood-isolated memory cells (Fig. 3.1A), indicate that after a 
transient period of DC-killing activity, activated CD8+ T cells enter a “helper phase” of their 
activation cycle. Similar termination of the suppressor phase of activity has also been observed 
in case of tissue-isolated effector cells (data not shown).  
 
Exogenous inhibitors of perforin- and Granzyme B restore DC-activating function of 
effector CD8+ T cells  
Prompted by the results of recent studies highlighting the role of perforin-/Granzyme B- and 
Fas/Fas-L pathways in CTL-mediated elimination of DCs in mouse (37, 119), we have analyzed 
the role of the perforin/Granzyme B- and Fas/Fas-L-mediated cytotoxic pathways in the killing 
of human DCs by effector CD8+ T cells. As shown in Figure 3.3A, DC killing was completely 
eliminated by the addition of EGTA or Concanamycin A (CMA), the inhibitors of the perforin-
dependent (but not Fas/Fas-L-dependent) pathway of CTL-mediated killing (120, 121). In 
contrast, no inhibition of DC killing was observed in the presence of the Fas-L antagonist 
(Supplementary Fig S4: Appendix A). 
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igure  3.3 3 Exogenous inhibitors of perforin/Granzyme B pathway convert effector-type CD8+ T cells  into F
helper CD8+ T cells. 
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(A) Inhibition of perforin in effector-type CD8+ T cells results in the survival of the interacting DCs. Release of 
functional perforin was blocked by either pre-treatment of the effector-type CD8+ T cells with CMA (100nM) or by 
the addition of EGTA (4mM) during DC-CD8 co-culture. The survival of DCs was analyzed by change in the light 
scatter properties (as indicated by dot plots: left), and verified using the NAO staining (right). Broken line within the 
dot plot separates live and dead cell populations. NAO analysis (right) included both regions (live and dead DCs). 
(B) Inhibition of perforin in effector-type CD8+ T cells results in the induction of their helper function, manifested 
by DC activation. CMA-treated effector-type CD8+ T cells were co-cultured with SEB loaded DCs for 48 hours. 
Left: CMA treated (perforin-blocked) effector-type CD8+ T cells enhance DC activation. TNFα (50ng/ml) induced 
DC maturation was used as positive control. Right: CMA treated (perforin-blocked) effector-type CD8+ T cells 
induce type-1 polarized phenotype in DCs, characterized by enhanced ability to produce IL-12p70. *: below 
detection limit. Results are representative of three independent experiments. (C) Inhibition of Granzyme B in 
effector-type CD8+ T cells results in survival of interacting DCs. Dendritic cells pretreated (1 hour) with IETD-CHO 
(200μM) or Z-IETD-fmk (20μM), were co-cultured with effector-type CD8+ T cells. Survival of DCs was analyzed 
after 10-12 hours. The data from two experiments are expressed as percent survival of DCs (mean ± SEM). 
 
Taking advantage of the relative stability of the CMA-induced perforin inhibition in 
CTLs, without affecting the secretion of CD8+ T cell-produced TNFα and IFNγ (Supplementary 
Fig. S4b: Appendix A), we analyzed the outcome of the interaction of the CMA-pre-treated 
effector cells with immature DCs. As shown in Figure 3.3B,  pre-treatment of the effector cells 
with CMA abrogated their DC-killing ability, resulting in the induction of phenotypic maturation 
of the DCs (TNFα was used as a control for DC maturation) and their priming for high IL-12p70 
production. Similar to the blocking of the perforin pathway, we also observed that pre-treatment 
of DCs with the specific Granzyme B inhibitors IETD-CHO or Z-IETD-fmk (122), abrogated the 
CTL-induced DC death (Fig. 3.3C).  
These results indicate that the perforin- and Granzyme B-mediated cytolytic pathway is 
the principal mode of DC elimination by human effector CD8+ T cells, and that, in its absence, 
the effector cells no longer suppress DC activity, but support it. These data also suggest that 
pharmacologic modulation of the perforin- or granzyme-mediated killing can be used to enhance 
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the effectiveness of active and adoptive immunotherapies performed in the setting of existing 
disease, where antigen-specific effector CD8+ T cells predominate.  
 
Memory CD8+ T cells protect DCs from CTL-mediated killing: Equivalent induction of the 
endogenous Granzyme B inhibitor, PI-9, by memory CD8+ and CD4+ T helper cells 
The inability of memory-type CD8+ T cells to kill DCs even after 48 hour co-cultures was 
particularly intriguing in face of our observations that their killing function can be restored 
following re-activation (Supplementary Fig. S 3c: Appendix A), and the data from mouse 
models that 30-72 hour-reactivated effector-memory and central-memory cells re-acquire their 
DC-killing potential (80, 123). These data suggested that the initial interaction of DCs with 
memory-type CD8+ T cells may protect DC from the eventually-acquired CTL activity of the 
same cells. In order to test this possibility, we have sequentially exposed DCs, first to memory-
type CD8+ T cells, followed by co-culture with effector-type CD8+ T cells.  
As shown in Figure 3.4A, the DCs exposed to memory-type CD8+ T cells became 
resistant to subsequent killing by CTLs. This protective effect of the memory-type CD8+ T cells 
was similar to that exerted by activated CD4+ T cells, the classical “helper T cells” (Fig. 3.4A) , 
which have been proposed to mediate their helper function by  DC protection (86, 99). In further 
support of the similarity between the helper functions of CD4+ T cells and CD8+ memory T cells, 
DCs that interacted with either of these T cell subsets expressed similar levels of an endogenous 
Granzyme B inhibitor PI-9 (Fig. 3.4B), a human equivalent of murine serine protease inhibitor 
(SPI-6) (124) shown to mediate the protection of mouse DCs from CTL-mediated killing (86). 
The analysis of PI-9 expression at the per cell basis, using confocal microscopy, revealed that PI-
9 is massively up-regulated in DCs within 2 hours following their interaction with memory-type 
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CD8+ T cells, with PI-9 expression being detectable in the individual DCs interacting with T 




























       
Figure  3.4 Memory-type CD8+ T cells and CD4+ T cells induce DC expression of endogenous Granzyme B 
inhibito om CTL–mediated killing. 
(A) Exposure of DCs to memory-type CD8+ T cells confers protection from effector-type CD8+ T cell mediated 
death, an ogous to CD4+ T cell mediated protection. Memory CD8+ T cells or CD4+ Th cells were co-cultured with 












NAO sta ng at 24 hours. (B) Memory-type CD8+ T cells induce uniform DCs expression of the endogenous 
Granzyme B inhibitor: PI-9 (10 hour co-culture). DCs exposed to memory-type CD8+ T cells, CD4+ T cells (or 
D40L: see the inset) were stained for intracellular PI-9. (C) Rapid induction of PI-9 in DCs exposed to memory-
type CD8+ T cells, visualized by confocal microscopy: Localization of PI-9 (red) in DCs (blue), following the 
raction with memory-type CD8+ T cells (green). Please note lack of PI-9 expression in isolated DCs, and high 
levels of PI9 expression in DCs in 2 hour co-cultures. 
The ability of CMA to abolish the DC-killing activity of CTLs without abrogating their 
ability to induce DC maturation, and our previous data that blocking of TNFα-RI (known to be 
triggered by TNFα and Lymphotoxin-β(LT)) abrogates DC maturation (83), prompted us to test 
if the CTL-protecting helper activ α and can 
be blocked by the addition of soluble TNF receptor I (blocking potential actions of TNFα and 






ity of memory-type CD8+ T cells is mediated by TNF
LT) or TNFα-specific antibody (Infliximab; blocking TNFα exclusively). In accordance with the 
key role of TNFα (rather than LT), both reagents proved equally effective in converting the 
memory T cell-induced DC activation into memory T cell-induced DC death (Fig. 3.5A, data not 
shown for sTNF-RI). As expected, these effects were accompanied by the prevention of the 
induction of PI-9 in DCs (Fig. 3.5B).  
Cs, we observed a significant release of TNFα within two hours of interaction of DC with 
memory-type CD8+ T cells, whereas the release of Granzyme B by memory-type CD8+ T cells 
was significant only at later time points. Effector T cells, however, simultaneously released both 
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α plays a 
Inhibition of TNFα activity abrogates the helper fun tion of mory-type CD8+ T cells, resulting in DC killing. 
Neutralization of TNFα in the co-cultures of SEB-l ed DCs and memory-type CD8+ T cells using anti-TNFα 
Effecto
 
                     
 











Figure  3.5 Memory-type CD8+ T cell-derived TNF crucial role in helper function. 
c  me
oad
an , r  DC survivtibody educes al (24 hour cultures). (B) anti-TNFα antibody, blocks the memory-type CD8+ T cell-
duce  PI-9 in DCs (10 hour time point). (C-D) Different relative kinetics of the TNFα- versus 
nzym  B release in m +  the interaction with DCs. Note that the release of 
α precede t not in effector cells. (E) Fo
fluorescent microscopy demonstrating the high amounts of Granzyme B (red) in the effecto
cells (bl nteracting (2 hours) with DC ut not in the memory CD8+ T cells (green). (F
TNFα (red) in both effector (blue) and me reen) CD8+ T cells interacting with DCs (grey).  Tw
cocultures. 
ore, the microscopic analysis of the DC - T cell interactions (at the 2 hour time 
point, when PI-9 is induced in DCs: see Fig. 3.4C) demonstrated equivalent mobilization of 
TNFα in both memory-type and effector-type CD8+ T cells (Fig. 3.5E), whereas exclusively the 
effector CD8+ T cells, but not memory cells, directed Granzyme B-containing cytotoxic granules 
towards the contact zone with DCs (Fig. 3.5F). This sequence of events indicates that the early 
Granzyme B. 
 of their ability to act as respective suppressor and helper cells during the de novo 
inducti
of naïve T cells but were also able to fully counteract the suppressive activity of effector CD8+ T 
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“CD8 to CD8 help” and “CD8 to CD4 help”: Memory CD8+ T cells support the de novo 
induction of CTLs and Th1 cells 
In support
on of type-1 immune cells, CD8+ T cells at different stages of activation differentially 
regulated the expansion of naïve CD8+ and CD4+ T cells and the development of their respective 
CTL and Th1 functions (Fig. 3.6A, B). Importantly, in accordance with the dominant role of 
memory CD8+ T cells in regulating the survival and function of DCs (see Fig. 3.4), the helper 
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Figure  3 mory CD8+ T cells support de novo induction of functional CTLs and Th1 cells.   
(A-B) Memory and effector CD8+ T cells have reciprocal impact on the DC-driven expansion of CTL- and Th1 cell 
progenit nd the development of CTL and Th1 functions. Blood-isolated naïve CD8+ or CD4+ T cells were 
primed with the SEB-loaded immature DCs in the absence or presence of γ-irradiated memory-type or effector-type 
CD8+ T cells. The expanding cultures of naïve CD8+ or CD4+ T cells were harvested, respectively at day 5 or day 
10, coun d and tested for their functional activity, using CTL assay or the analysis of their Th1/Th2 cytokine 
profiles. (A) Memory CD8+ T cells support the expansion of CTL precursors and their acquisition of functional 





















ity. Left: CTL activity of CD8+ T cell cultures performed in the presence or absence of memory or effector 
CD8+ T cells was assessed by 51Cr release assay, using SEB-loaded JY-1 cells as targets. Data from one of two 
indepen nt experiments, that both yielded similar results.  (B) Memory CD8+ T cells support the expansion of Th1 
cell prec sors and the acquisition of Th1 cytokine production profiles.  Right: Ability of memory-type CD8+ T 
cells, but not effector-type CD8+ T cells, to induce naïve CD4+ T cell proliferation. Left: Naïve CD4+ T cells primed 
in the presence of memory-type CD8+ T cells develop a strongly polarized Th1 cytokine profile as determined by 




s “danger signals” or 
DAMPs) (10, 11), implicating the need for a significant pathogen load and tissue damage. In 
ras  of DCs during secondary responses can benefit from the activating 





We show that in contrast to effector CD8+ T cells which rapidly eliminate antigen-c
in a perforin- and Granzyme B-dependent mechanism, human memory CD8+ T cells protect DCs 
from CTL-mediated killing and exert DC-mediated helper function. These data indicate that the 
mechanism of CD8+ T cell memory, in addi  previously defined increased frequency of 
Ag-specific T cells and their rapid acquisition of effector functions, involves a novel CD4+ T 
cell-like ability of memory CD8+ T cells to prolong the life-span of antigen-carrying DCs.  
Our data support the following functional model of CD8+ T cell memory: During primary 
immune responses, DC activation requires their exposure to factors representing pathogen-
associated- or tissue damage-associated molecular patterns (PAMPs versu
cont t, the activation
the destruction of the infected cells and the release of additional copies of the pathogen. Such 
memory CD8+ T cell-dependent early DC activation helps the immune system to respond to the 
pathogen at much earlier stages of (re)infection, limiting its early spread, the extent of tissue 
damage and the activation of innate defense mechanisms, thus preventing the onset of disease 
symptoms.  
Moreover, since during the primary responses, the PAMP- and DAMP-mediated DC 
pro
In addition to the currently-identified DC protection by memory CD8  T cells, recall 
immunity may also benefit from the IFNγ-dependent (83) ability of memory CD8  T cells to 
enhance the DC secretion of IL-12p70 (Fig. 3.1B and 3.2B), jointly contributing to the superior 
mag
The current demonstration of the dominant impact of memory CD8  T cells in preventing 
DC killing by existing CTLs and promoting the optimal de novo induction of functional CTLs 
and Th1 cells facilitate the development of new vaccination strategies in therapeutic settings. In 
accordance with such a possibility, our in vivo observations in mouse demonstrate that the 
inclusion in tumor vaccines of tumor-unrelated helper epitopes, promoting the interaction of the 
vaccine-carrying DCs with tumor-unrelated memory CD8  T cells, can boost the immunologic 
and anti-tumor effects of vaccination against established tumors (manuscript in press). The 
tection from newly arising CTLs is limited to the period of active infection and ongoing 
tissue damage, the optimal activation of the T cells recruited to the lymph nodes at later stages of 
primary responses (needed for the optimal development of memory cells (125, 126)) is 
dependent on DC-protecting signals from CD4+ T helper cells (99). In contrast, during secondary 
immune responses, antigen-carrying DCs can also interact with the CD8+ memory T cells that are 
gradually recruited to the sites of infection or to inflamed lymph nodes, preventing premature 
DC elimination by the arising effector cells and limiting their dependence on the pathogen-
related or CD4+ T cell-related survival signals.  
+
+





ory cells to 
provide
72 hours (but not 24 hours) of antigenic challenge 
(80) and human central memory CD8+ T cells have been shown to need up to 72 hours of 
activation to re-acquire the cytotoxic function (127), the DC protection by central memory T 
cells during secondary immune responses is likely to have a substantial time-span.  
 data also help to explain the high efficacy of prime-boost vaccination strategies (75), 
when the first and second doses of vaccine are delivered using antigenically-distinct vectors and 
may help to further improve such strategies. 
We are currently comparing the ability of different populations of mem
 helper signals. While our preliminary data suggest that blood-isolated central-memory 
and effector-memory CD8+ T cells are both effective in protecting DCs from CTL killing (not 
shown), we observed that the memory-type cells generated in our two week-long cultures (in 
contrast to blood-isolated memory cells, expressing low levels of Granzyme-B and perforin: see 
Figs. 3.1 and 3.2) can re-acquire the DC killing ability following short-term restimulation 
(Supplementary Figure S 3c: Appendix A). These data, and the recently-published observations 
that mouse effector-memory CD8+ T cells can acquire DC-killing capacity in vivo within 30 
hours of exposure to antigen-loaded DCs (123), suggest that an optimal long-term DC protection 
in vivo may require the presence of central memory cells. Since mouse long-term memory cells 
have been shown to kill DC only following 
An intriguing aspect of the current findings is the possibility of manipulating the respective 
suppressive and helper functions of effector and memory CD8+ T cells, using pharmacologic 
agents.  We observed that blocking perforin or Granzyme B activity results in the acquisition of 
helper functions by the effector cells, while blocking TNFα interaction with TNF-RI converts 
memory T cells into suppressive cells. These data have direct pathologic and therapeutic 
implications for autoimmunity, chronic infections and cancer. While the blockade of TNFα or 
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TNF-RI, using Infliximab or Eternacept, respectively, proved to be highly effective in the 
treatment of inflammatory bowel disease, rheumatoid arthritis, and other autoimmune diseases, a 
comparative evaluation of the role of these agents in limiting the DC-activating functions of 
CD8+ T cells in these different disease settings may help to explain the differential efficacy of 
each of these agents in patients with different forms of autoimmunity, allowing further 
optimization of their treatment. 
While the inability of perforin-deficient CD8+ T cells (and possibly NK cells) to control 
CD8+ T cell expansion has been proposed to explain autoimmune damage in perforin knockout 
mice infected with LCMV or Listeria (128), and the uncontrolled lymphoproliferation during 
viral infections in patients with perforin mutations (129), the current data provide the rationale 
for the evaluation of perforin or granzyme-targeting therapies as a tool to increase the efficacy of 
therapeutic vaccines in the settings of cancer and chronic infections, where terminally 
differentiated effector cells predominate (96, 98, 130).  It also remains to be tested whether 
perforin- or granzyme-targeting approaches can be applied to enhance the long-term clinical 
effectiveness of adoptive immunotherapies with ex-vivo expanded tumor-infiltrating 
lymphocytes, where the long-term persistence of tumor-specific T cells and the positive clinical 
outcomes are tightly-correlated with the frequencies of the adoptively-transferred memory-type, 
expectedly non-DC-killing, CD8+ T cells (131-133). 
In summary, the current data help to reconcile the long-known paradoxical ability of 
CD8+ T cells to play the reciprocal “suppressor” and “helper” roles, adding to our understanding 
of CD8+ T cell memory, and facilitating the development of effective therapies of autoimmunity, 
cancer and chronic infections. 
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Effective CD8+ T cell responses require T cell expansion and the development of the effector 
 interferons and TLR ligands, expand and acquire IL-7R 
 and undergo a switch in chemokine (CK) 
responsiveness (from lymphoid to peripheral).   In contrast, CD8+ T cells activated by long-term-
stimulated “exhausted” DCs or by DCs exposed to mediators of chronic inflammation, such as 
PGE2, effectively expand and acquire IL-7R /IL-15R  phenotype while retaining the 
CD62L CCR7+CCR5- central memory phenotype not associated with CTL functions. The “non-
cytolytic/lymphoid” status induced in naive or memory (including tumor-specific) CD8+ T cells 
by the PGE2-matured DCs is fully reversed by the interaction with inflammatory-type DCs, 
suggesting that the non-cytolytic T cells are fully functional but undergo memory-type 
differentiation. The independent regulation of CD8+ T cell expansion and their commitment to 
the peripheral/effector versus lymphoid/memory subsets helps to understand the  phenomenon of 
preferential induction of memory CD8+ T cells at late stages of immune responses and the 
negative impact of persistent inflammation on the development of immune memory. The limited 
DENDRITIC CELLS REGULATE THE LYMPHOID VERSUS PERIPHERA
EFFECTOR PATHWAY OF DIFFERENTIATION OF CD8+ T CELLS. 
4.1 ABSTRACT 
(CTLs) and memory cells. Here, we report that CD8+ T cells stimulated by the “inflammatory-
type” dendritic cells (DC) activated by




effectiveness of PGE2-matured DCs in inducing peripheral-tissue-directing chemokine receptors 
on tumor-specific T cells helps to explain the limited clinical effectiveness of the current cancer 
vaccines, suggesting novel ways of enhancing their therapeutic effectiveness.  
4.2 INTRODUCTION 
regulate the proliferation and differentiation of CD8+ T cells. While the 
combination of “signal 1” (antigen) and “signal 2” (co-stimulation) is known to be essential for 
the induction of CD8  T cell proliferation and clonal expansion (134)(135)(136), it is less clear 
what signals govern their differentiation towards the effector cells (CTLs) with immediate 
cytolytic  function, and tissue/peripheral homing capacity, as opposed to memory cells that retain 
the lymphoid/central homing pattern and lack immediate killing function (46, 47).  
In case of CD4  T cells, studies in human and mouse models have demonstrated that the 
DC-induced expansion of naïve CD4  T cells can be uncoupled from their acquisition of Th1 or 
Th2 effector functions (13, 15, 16, 92, 115, 137), leading to the concept of “signal 3” (13) which 
selectively regulates the acquisition of T cell effector functions. While no similar data are 
available in the case of CD8  T cells, increasing evidence suggests a key role of inflammation in 
the development of cytolytic function and the requirement for its cessation in the effective 
transition from the effector to memory phase of immunity (138, 139). Several in vivo models of 
infections have demonstrated that inflammatory cytokines such as IL-12, IFNα and IFNγ, are 
involved not only in the regulation of proliferation of CD8  T cells but also in their acquisition of 
effector functions (140-142). There is also increasing evidence suggesting that active 
inflammation can  delay the formation of memory  CD8  T cells  (48, 54), with the induction of 








memory CD8+ T cells being particularly effective at late stages of immune responses, following 
the termination of the inflammation-inducing active stage of the pathogenic infection. Moreover, 
the observations of prominent expansion of tumor-specific CD8+ T cells in the blood of patients 
treated with current cancer vaccines in combination with limited induction of their effector 
functions or clinical activity of vaccination, together with the ability of inflammatory cytokines 
on tic T cells into cytolytic ones suggest a similar inflammation-
dependent regulation of the effector versus memory phases of immune responses in humans (21, 
131). 
In order to address the role of dendritic cells in the development of human effector and 
memory CD8  T cells, we compared the magnitude and quality of CD8  T cell responses 
induced by the DCs activated in acute or chronic fashion by different inflammatory mediators.  
Our data indicate that DCs matured under conditions mimicking an early phase of immune 
response (short-term activation with inflammatory cytokines and TLR ligands) promote the 
effector pathway of CD8 T cells differentiation, followed by the development of non-cytolytic 
memory cells. In contrast, DC matured during the late phase of immune response (activation 
with inflammatory cytokines or prolonged exposure to inflammation) supported CD8  T cell 
expansion and direct differentiation into memory cells, without inducing their cytolytic function 
 
 




and a switch in chemokine responsiveness .  
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4.3 MATERIALS AND METHODS 
Cell lines, media and reagents 
Serum-free AIM-V medium (Invitrogen, Carlsbad, CA) was to used to generate DCs and IMDM 
(Invitrogen) with 5% human serum (Atlanta Biologicals, Norcross, GA) was used for in vitro 
sensitization (IVS) experiments. The following factors were used to generate mature DCs: rhu 
GM-CSF and IL-4 (gifts from Schering Plough, Kenilworth, NJ), IFNα (Intron A-IFNα-2b; 
Schering Plough, NJ), rhuTNFα, rhuIFNγ, rhu IL-1β (all Strathmann Biotech, Germany), rhuIL-
6 (Gen
ng/ml), LPS and IFNγ (1000U/ml), LPS and PGE2 
(10-6 m /ml), TNFα (100ng/ml) and IFNγ, TNFα and PGE2, TNFα, IL-1β (25ng/ml), PGE2, IL-6 
(1000U/ml) and αDC1 maturation cocktail as described (112). 
Isolation of Peripheral Blood CD8+ T cell Populations 
Naïve CD8+CD45RA+ T cells were isolated by negative selection with the StemSep and CD8 
enrichment cocktails, respectively (StemCell Technologies Inc, Vancouver, Canada). 
zyme, Cambridge, MA), lipopolysaccharide (Sigma, St. Louis, MO), PGE2 (Sigma) and 
poly I: C (Sigma). IL-2 (Chiron Corp, Emeryville, CA) and rhuIL-7 (Strathmann Biotech) were 
used to support the CD8+ T cell expansion.  
Generation and maturation of dendritic cells 
Peripheral blood mononuclear cells (PBMCs) were obtained from the blood of healthy donors or 
melanoma patients using lymphocyte separation medium (Cellgro Mediatech, Herndon, VA). 
Monocytes were isolated on density gradients, with Percoll (Sigma), followed by plastic 
adherence. Monocytes were cultured for 6 days in 24-well plates (Falcon) at 5x105 cells per well 
in rhuGM-CSF and IL-4 (both 1000U/ml). The following combinations of maturation stimuli 
were added to DCs on day 6: LPS alone (250
ol
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Biot lated anti-CD45RO antibody was iny used in combination with enrichment cocktail for 
isolation of naïve population. CD8+CCR7+CD45RA- central memory T cell population was flow-
cell sorter (Dako Cytomation), after labeling with appropriate 
iences and BD Pharmingen respectively. HLA-
lter, Immunomics) was performed according to 




Two- and three-color cell surface and intracellular immunostaining analysis was performed using 
Beckman Coulter Epics XL flow cytometer. FITC and PE-labeled anti human CCR7 (R&D 
Systems), CCR5 (BD Pharmingen), CXCR3 (BD Pharmingen) and the corresponding isotypes 
IgG2a and IgG1 were used. PE-labeled anti-human Granzyme B and FITC-anti human perforin 
antibodies were purchased from Cell Sc
A2/MART127-35 tetramer staining (Beckman Cou
the manufacturer’s instructions.  
In vitro sensitization 
Naïve CD8+CD45RA+CCR7high T cells (5x105 cells/well) were activated with SEB-pulsed DCs 
(5x104 cells/well). On day 5-6, expanded CD8+ T cells were used for immunostaining; 
alternatively the cultures were fed with low dose IL-2 and IL-7 (10ng/ml) every two days and 




Cytolytic and non-cytolytic differentiation of CD8+ T cells induced by “inflammatory” 
versus “exhausted” DCs  
 order to delineate the requirements for the effective DC-induced expansion of CD8+ T cells 
ion of effector functions, we compared the outcome of naïve CD8+ T cell 
e the inset) demonstrated an effective induction of granzyme B 
g S6) (Fig. 4.1A left), the marker of the effector pathway of T cell 
 contrast to the situation with short term-activated DCs, long-term activated DCs (96 
hours) generally induced much lower levels of granzyme B expression, and independently from 
the character of the maturation-inducing stimulus (Fig. 4.1B right). This observation is 
consistent with the exhausted status (13, 15) of such long-term-activated DCs, and their low 
activity in inducing functional Th1 responses (15). 
In
and their acquisit
priming by DCs induced to mature by the mediators of acute inflammation (combination of 
interferons and TLR ligands) or by mediators of chronic inflammation (presence of PGE2), either 
for 24 hours or 96 hours.. The short versus prolonged maturation of DCs is associated with 
differential ability to produce IL-12p70 (13), the key mediator of inflammatory-type responses 
(143), and  with different abilities to induce Th1 responses of CD4+ Th cells (13, 15).  
Naïve CD8+ T cells primed by the short term-matured (24 hours) inflammatory-type DCs 
(high IL-12-producing activity; se
(and Granzyme A; Fi
differentiation (31). Poor effectiveness of “exhausted”  DC in inducing Granzyme B+ T cells, did 
not simply result from an ineffective activation of naive T cells, since the proliferation of T cells 
in these cultures was similar or usually even higher compared to the T cells activated by 
“inflammatory” DCs (Supplementary Fig. S6: appendix B).  
In
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These results indicate that the conditions of DC activation and its duration determine the 
ability of DCs to induce the cytotoxic function of CD8+ T cells, while being less relevant for the 
n of Granzyme B correlated with the superior cytolytic function of 
induction of CD8+ T cell proliferation.  
Indeed, the inductio
CD8+ T cells primed by the inflammatory-type DCs (Fig 4.1B, C). In contrast, priming by the 
“exhausted” DCs led to low levels of granzyme B and perforin and the associated poor ability to 
kill antigen-pulsed target cells.  The outcome of these experiments indicate that, in analogy to the 
DC-induced differentiation of CD4+ T cells into Th1 and Th2 direction (13), the expansion of 
CD8+ T can be uncoupled from their effector-type differentiation, and that CD8+ T cell 
expansion induced by chronically stimulated “exhausted” DCs is not accompanied by the 







































T cell expression of granzyme B (δMFI) T cell expression of granzyme B (δMFI)



























   
Figure  Induction of cytolytic and non-cytolytic pathway of CD8+ T cell differentiation by, respectively, 
short-term activated and exhausted DCs. 
(A) Immature DCs were activated with different combination of cytokines (details in Materials and Methods) for 24 
hours. Naïve CD8+ T cells were primed with activated DCs. On day 5, CD8+ T cells were counted to assess 
prolifera on (see appendix B for data on cell number) and intracellular staining for granzyme B was performed. 
Inset: IL 2p70 production from differentially activated DCs after CD40L stimulation, * denotes not detectable. 
Persisten  activation (96 hours) of DCs with the different combinations of cytokines (see Materials and Methods). 
Naïve C 8+ T cells were primed with chronically activated (96 hours) DCs. On day 5, CD8+ T cells were counted to 
assess p iferation (see appendix B for data on cell number) and intracellular staining for granzyme B was 
perform . Inset: IL-12p70 production from differentially activated DCs after CD40L stimulation, * denotes not 
detectab . (B) Cytolytic function of CD8+ T cells, primed with either inflammatory DCs (αDC1s) or exhausted DCs 
(sDCs), was assessed by standard 51Cr-release assay. (C) Intracellular levels of cytolytic granules granzyme B and 
















quirement for inflammatory-type DCs for the acquisition of peripheral chemokine 
 
r 
panel), the chemokine receptor involved in peripheral homing of effector CD8  T cells (144), 
Unexpectedly, CD8+ T cells stimulated with the “exhausted” PGE2-matured DCs retained high 
levels of CCR7 expression, a lymphoid homing receptor (and a marker of naïve and central 
memory T cells), and did not acquire CCR5 (Fig. 4.2A bottom panel). We are currently 
analyzing the responsiveness of differentially primed CD8+ T cells to chemokines CCL5 and 
CCL21
In an attempt to determine the mechanism of the inflammatory-type DC-induced switch 
ve analyzed the impact of several of the 
inflamm
IL-23, IL-27, and IL-18 (112) and (Supplementary Fig S8 , the 
ddition of IL-12 during the priming of naïve CD8+ T cells by the “exhausted” DCs resulted in 
0-70% of the cells. In accord with the key role of DC-produced IL-12 in 
e induction of the lymphoid-to-peripheral switch in chemokine responsiveness, the 
ng T cell priming abrogated the differences between αDC1 and sDC 
(Fig. 4.2B-right), preventing the down-regulation of CCR7. Our preliminary results indicate that 
Re
responsiveness in activated CD8+ T cells.   
Since the inflammatory and exhausted DCs showed differential impact on the induction of CTL 
function in naive T cells, we tested their influence on the expression of the peripheral-type versus 
LN-type chemokine receptors on CD8+ T cells. 
As shown in Figure 4.2A, inflammatory DCs induced the down regulation of CCR7 on
50-70% of CD8+ T cells and their simultaneous acquisition of CCR5 expression (Fig. 4.2A uppe
+
. 
in the chemokine receptor pattern of CD8+ T cells, we ha
atory-type cytokines differentially expressed by αDC1s and sDCs; such as IL-12p70, 
). As shown in Figure 4.2B
a
the loss of CCR7 on 3
th
neutralization of IL-12 duri




of CCR7 on the CD8+ T cells and we are currently analyzing the influence of the combination of 
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CCR5 and CXCR3 and flow cytometry was performed. (B) Recombinant IL-12 was added during the priming of 
dded during the priming of naïve CD8+ T cells by αDC1 and CCR7 expression was assessed by flow 






+ T cells and sDC-primed CD8+ T cells were stained on day 5-6 for chemokine receptors CCR7, 







kines mediating long-term survival of primed CD8+ T cells 
, DC1-primed cells. In addition, the 
Fig. 
4.3B mory T cells (Fig. 4.3C).  
s expected, similar to the in vitro generated non-cytolytic CD8+ T cells induced by non-
inflamm tory DCs, blood-isolated central memory CD8+ T cells acquired cytolytic effector 







“Exhausted” DCs induce CD8+ T cells with central-memory phenotype and function  
Since the priming of naïve CD8+ T cells with exhausted DCs led to the expansion of CD8+ T 
cells with persistent expression of CCR7 and CD62L and the absence of effector function, we 
asked whether such non-effector pathway of CD8+ T cell activation represents an abortive 
pathway of differentiation, or an alternative pathway of differentiation of the functionally intact 
cells. As shown in Figure 4.3A, in addition to CCR7 and CD62L, the sDC-primed T cells 
expressed typical markers of central-memory cells, such as IL-15Rα, and IL-7R (CD127), the 
receptors for the homeostatic cyto
(27 145), making such cells indistinguishable from the α
sDC-primed non-cytolytic CCR7+ cells were capable of acquiring cytolytic activity and the 
peripheral-type chemokine receptor profile, upon restimulation with inflammatory DCs (




inflammatory DCs but not with “exhausted” DCs (Fig. 4.3C).  
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Central memory CD8+ T cells, restimulation by αDC1 
  
C 
, CD62L, IL-15Rα and CD127 on 
primed C 8+ T cells was measured on day 20-25. (B) CD8+ T cells primed initially with sDCs, expanded for 14 
B          
     




     
    
Figure  4.3 Induction of central-memory phenotype in CD8+ T cells primed by exhausted DCs and their 
similarity to blood derived central memory T cells. 




days, were restimulated with αDC1s. After restimulation, on day 5 their cytotoxic ability was assessed by 51Cr 
release assay and expression of CCR7 and CCR5 was measured by flow cytometry. (C) CD8+ central memory T 
cells we  sorted from peripheral blood and stimulated with αDC1s or sDCs. On day 5, cytolytic potential was 
sessed by 51Cr release assay, and chemokine receptor expression evaluated by flow cytometry. 
 
Inflammatory and exhausted DC differentially regulate CTL activity and tumor-relevant 
chemokine receptors on tumor-specific CD8+ T cells 
Prompted by the results of the experiments with polyclonally-activated naïve and memory CD8+ 
-restricted 




 the induction of CTL responses with strongly el
f CD8+ T cells expressing high levels of CCR5. Since  CXCR3,  another peripheral-type 
hemokine receptor, has been implicated in the anti-tumor effectiveness of tumor-specific CD8+ 
 cells (146) we also analyzed the  expression of CXCR3 on tumor-specific CD8+ T cells after 
 inflammatory or exhausted DCs. As shown in Figure 4.4, in accordance 
with the data obtained in polyclonal models, the inflammatory DCs proved superior in inducing 
Granzyme B expression in MART-1-tetramer-positive T cells (Fig. 4.4A), that were superior in 
their ability to kill MART-1- expressing tumor melanoma cell line (Fig. 4.4B). αDC1-stimulated 
CD8+ T cells also induced elevated expression of CXCR3 and CCR5 on MART-1 tetramer-
positive cells (Fig. 4.4C).   
re
as
T cells, we have compared the outcome of in vitro sensitization (IVS) of HLA-A2
lanoma-specific CD8+ T cells, using MART127-35-loaded autologous αDC1 or sDCs
immunogen (112). In contrast to the short-term experiments performed in a polyclonal system
the generation of high numbers of MART-1-specific T cells required prolonged culture of the 
ed cells.  
While in these culture conditions we could not detect the differences in CCR7 expression (data 
not shown), the IVS experiments performed using the pro-inflammatory DCs (
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was measured on 
MART1 gated CD8  T cells. (B) Cytotoxic activity of the CTLs induced by sDCs or αDC1 was measured against 
control tumor cell line (not expressing MART1) and MART1 expressing Fem X cell line. Similar results were 






Figure  4.4 Inflammatory and exhausted DC induced differential expression of Granzyme B, CCR5 and 
CXCR3 on tumor-specific CD8+ T cells. 
αDC1s or sDC from HLA-A2+ melanoma patients were pulsed with HLA-A2 restricted MART1 peptide and used to 




 functions and a switch in their chemokine responsiveness was a sole property of 
+
+ lo lo + - -
+ lo lo + + +
+
responsiveness to the peripheral/inflammatory-
okines, the CD8+ T cells activated by either long-term activated DCs, or the DCs 
 showed high level of cell expansion, but failed to 
okine responsiveness and to acquire CTL functions. Our data shows 
the functional and phenotypical similarity between such cells and central-memory cells isolated 
Our data demonstrate that in analogy to the DC-induced differentiation of CD4+ Th cells into 
Th1 and Th2 direction, the functional differentiation of naïve and resting memory CD8+ T cells 
is differentially regulated by the “inflammatory-type” and “exhausted” DCs. We observed that 
while the proliferation and expansion of CD8+ T cells can be driven efficiently by the DCs 
undergoing maturation in a wide spectrum of inflammatory conditions, the induction of the CD8+ 
T cell effector
the IL-12-producing DCs activated for a short period of time in the conditions mimicking acute 
inflammation (presence of interferons and TLR ligands). 
Such an inflammatory pathway of activation of CD8  T cells resulted in roughly equal 
numbers of the cells acquiring the CD8 GrB Prf CCR5 CD62L CCR7  effector-memory 
phenotype, and the CD8 GrB Prf CCR5 CD62L CCR7  intermediate/central-memory 
phenotype. Interestingly, in accordance with the previously-reported long-lived potential of the 
cells activated by the pro-inflammatory high IL-12-producing DCs (112) and with the ability of 
recombinant IL-12 to promote CTL  survival (39, 147), both these subsets expressed high levels 
of IL-7- and IL-15 receptors (Fig. 4.3), known to be essential for the homeostatic proliferation 
and long term survival of CD8  T cells in vivo (27, 145). In contrast to such cytolytic/effector 
pathway of differentiation associated with the termination of responsiveness to the lymph-node-
associated chemokines and the acquisition of the 
type chem
induced to mature in the presence of PGE2
undergo the switch in chem
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om peripheral blood. In addition, high expression of IL-7R and IL-15R and the accelerated 
ability of such non-cytolytic cells to acquire effector function following (re)stimulation by the 
inflammatory DCs, suggest that such non-cytolytic pathway of CD8+ T cell differentiation, 
induced by the “exhausted” DCs represents a direct pathway of development of the memory 
cells, an alternative to their “indirect” pathway of development via an intermediate effector 
stage. 
We have shown that the differential ability of DCs to direct naïve T cells to either of 
these pathways (effector/effector-memory versus central memory) depends on the duration of 
e differences in the DC-mediated IL-12 ng 
echanism.  
These data help to explain several of the phenomena relevant to the generation of CD8+ T 
ell memory: mouse studies have revealed the need for early inflammation following an 
fection or DC immunization in order to generate a robust effector response (138). The 
pplication of antibiotics to shorten the duration of infection (55) (56) was shown to accelerate 
n whether memory and effector cells represent alternative 
troversy, showing that differentiation of 
aïve CD8+ T cells into memory cells can occur through either pathway, either directly into 
memory compartment, or through an indirect pathway associated with a (transient) acquisition of 
fr
DC activation and the character of the inflammatory environment driving DCs activation, with 





the formation of CD8+ memory T cells.  
The current debate centers o
parallel pathways of T cell differentiation or sequential stages of T cell activation, with 
contrasting answers to this question obtained with different experimental systems (49, 50, 56).  
Our current results help to reconcile this con
n
the e ector function byff  at least a proportion of the cells. This decision is dependent on the 
stage/character of DC activation.  
ctions, the over-differentiation of the 
adoptiv
c
The current in vitro results are also in accordance with the observed results of numerous 
clinical trials for cancer immunotherapy (59). Active immunotherapy approaches such as peptide 
or viral vector-mediated immunization result in massive expansion in the number of tumor-
specific CD8+ T cells but with negligible effector function and poor induction of clinical 
responses (21, 131), that could only be reversed into the effector-type responses, when followed 
by IFNα (21). Similar to vaccines (active immunotherapies), adoptive immunotherapy with ex-
vivo expanded tumor-specific CD8+ T cells has met with little success.  While tumor-isolated T 
cells used in these trials show high ex vivo effector fun
ely transferred CD8+ T cells results in their relatively short half-life and can limit their 
clinical effectiveness, compared to less differentiated T ells (148-150) (151).  
The current data demonstrating the possibility of exploiting the activation pathway of 
DCs in order to selectively promote either the effector or the memory pathway of CD8+ T cells 
differentiation, facilitates the adjustment of the currently-used (active and adoptive) 
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5 ALTERNATIVE TWO-SIGNAL-DEPENDENT HELPER ACTIVITY OF CD8+ T 
CELLS  
 TCR ligation to 
exert D
TCR dependent 
timuli is tightly regulated since each of the cytokine signals by itself is ineffective. Alternative 
o-signal-activated CD8+ T cells induce DC maturation and prime them for enhanced IL-12p70 
roduction following subsequent stimulation with CD40L. The current data indicate that while 
rimed CD8+ T cells can be activated by inflammatory cytokines in a TCR-independent manner 
to perform immunoregulatory role, such activity remains to be tightly regulated in a “two-signal” 
paradigm. TCR independent activation of CD8+ T cells can allow local IFNγ delivery and DC 
activation during responses against MHC-deficient cells, and helps to explain the role of non-
 
5.1 ABSTRACT 
We have previously demonstrated the ability of resting CD8+ T cells to program DCs for 
induction of type-1 immune response. This “helper function” of Ag-activated CD8+ T cells 
requires TCR triggering and is mediated by TNFα and IFNγ. Here we show that in contrast to 
resting CD8+ T cells, pre-activated CD8+ T cells are no longer dependent on
C-mediated immunoregulatory function, but can utilize the cues from the mediators of 
innate response such as IFNα and IL-18. Non-TCR dependent “alternative two-signal” activation 
is equivalent to TCR based signal with regards to induction of “helper activity” of primed CD8+ 






antigen specific T cells within inflammatory infiltrates in tuberculosis, leprosy, and allergic 
reactions. 
5.2 INTRODUCTION 
The C in elimination of 
transformed and virally infected cells (36). Naïve CD8+ T cells require signal 1 (antigen), signal 
ffector 
functions in antigen-experienced memory CD8+ T lymphocytes requires lower activation 
threshold (47, 73), allowing them to respond to antigen already in the conditions of a limited 
tissue damage. In addition, memory cells also express increased levels of receptors for cytokines 
such as IL-15, IL-7, and IL-18 (45, 145, 152, 153). 
Recent studies have shown that CD8 T cells are not only effector cells of adaptive 
immunity but also participate in early phase of the immune responses (154). Studies in mouse 
models of intracellular infections such as Listeria and melioidosis (39, 40) have shown that CD8+ 
T cells can secrete IFNγ in response to pro-inflammatory cytokines such as IL-12, IL-18, and 
IFNα. IFNα, secreted by plasmacytoid DCs and other infected cells, plays both a pro-
inflammatory effector role in innate responses by exerting a direct anti-viral effect, as well as can 
have an immunoregulatory role during adaptive immune responses (155, 156).  Another innate 
cytokine is IL-18, which is secreted by macrophages, dendritic cells (DCs), keratinocytes, and 
epithelial cells (81, 157). 
D8+ T cell mediated adaptive immune response plays a key role 
2 (costimulation), and polarizing signal 3, in order to undergo clonal expansion and to 
differentiate into functional effector CD8+ T cells (CTLs). In contrast, induction of the e
+ 
 85 
Prompted by the studies showing the contribution of IL-12, or IFNα, and IL-18  to the 
induction of IFNγ in NK cells and T cells (45, 158), in the current this study we addressed (i) the  
regulatory requirements for such cytokine mediated ( TCR-independent  CD8+ T cell activation, 
(ii) impact of alternatively activated CD8+ T cells on DCs. 
The results presented here demonstrate that the previously activated CD8+ T cells share the 
paradigm of two-signal activation with NK cells (158), being TCR-independent but requiring a 
ltaneous exposure to at least two different inflammatory signals. This alternative two-signal 
activation mechanism is an exclusive feature of CD8+ T cells that have undergone prior TCR-
5.3 MATERIALS AND METHODS 
Culture media, reagents and cell lines. Cell lines and human DCs were cultured in IMDM 
(Invitrogen, Carlsbad, CA) containing L-glutamine and 10% FBS (Hyclone, Logan, UT). The 
following reagents were used to activate CD8  T cells: IFNα (Intron A-IFNα-2b; Schering 
Plough, NJ), recombinant human IL-18 (MBL International, Woburn, MA), recombinant human 
IL-15 (R&D Systems, Minneapolis, MN). Anti-human CD3 and CD28 stimulating mAb’s were 
purchased from CLB. The following reagents were used to obtain immature DCs: rhuGM-CSF 
and rhuIL-4 (gifts from Schering Plough). The CD40L transfected J588 plasmacytoma cell line 
was a gift from P. Lane (University of Birmingham, UK). 
Cell Isolation. Mononuclear cells from peripheral blood of healthy donors were isolated using 
Lymphocyte Separation Medium (Cellgro, Mediatech). Monocytes were isolated from the 
mononuclear fraction using Percoll (Sigma) density separation technique, followed by plastic 
simu
mediated activation and allows the bystander cells to perform DC-mediated “helper” function. 
+
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adherence, as described (137). Resting CD8+ T cells were isolated by negative selection using 
Stemsep CD8+ T cell enrichment cocktail (Stemcell Technologies Inc, Canada).  
Cytokine production by primed CD8+ T cells. Primed CD8+ T cells (resting CD8+ T cells were 
stimulated with CD3/CD28 activating antibodies for 6 days) were plated in 96-well flat bottomed 
 The untreated CD8+ T cells or single cytokines –IL-18, IFNα or IL-
15 were controls for spontaneous IFNγ and TNFα production. IFNγ and TNFα levels in 24h 
supernatants were measured by ELISA. 
Activation and polarization of DCs by primed CD8+ T cells.  Primed CD8  T cells (2 x10
cells) were added to day 6 immature DC culture (2-3 x 105 cells/well) in the presence or absence 
of OKT3 (positive control) or IFNα (3000U/ml) and IL-18 (100μg/ml). After 48 hours, the cells 
were harvested and analyzed for the expression of maturation-associated surface markers and the 
ability to produce IL-12p70. To test IL-12p70 producing capacity of DCs, the harvested DCs 
were plated in 96-well flat-bottomed plate (2x 104 cells/ well) along with CD40L transfected 


















and induction of IFNγ (Fig. 5.1A right). In contrast to primed T cells, resting CD8+ T cells are 
not responsive to these inflammatory mediators, alone or in combinations (Fig. 5.1A left). 
bination of IL-15 and IL-18 was used to 
activate primed CD8+ T cells (Fig. 5.1C left). In addition, IFNα and NK cell ligands present on 
the surface of K562 and Hela cells synergistically induce IFNγ  secretion in primed CD8+ T cells 
(Fig. 5.1C right). A similar two signal activation requirement has been observed in case of 









Primed CD8 T cells can be reactivated by proinflammatory cytokines: alternative two-
signal paradigm of activation of CD8 T cells 
The requirements for antigen specific activation of CD8 T cells are known, but regulatory 
requirements for cytokine mediated CD8 T cell activation have not been investigated till now. 
We observed that the responsiveness of primed CD8 T cells to IFNα or IL-18 is tightly 
regulated, as single cytokine- IFNα or IL-18 by itself did not induce significant IFNγ production 
in primed CD8+ T cells. The combination of IFNα and IL-18 had synergistic effect on activatio
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Figure  5.1 Two-signal requirement for the induction of IFNγ and TNFα production by primed CD8+ T cells 
(A, B) In contrast to resting CD8+ T cells, primed CD8+ T cells secrete IFNγ and TNFα in response to combination 
of IFNα and IL-18 in vitro. Resting or primed CD8+ T cells were cultured for 24 hours with cytokines or TCR 
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us pernatants were assayed for IFNγ production by ELISA. (C, D) Similar to IFNα and IL-
18, two other combinations-IL-15 and IL-18 and IFNα and target cell K562 or Hela cells also elicited IFNγ 










Figure  5  “Alternate” two-signal activated CD8+ T cells induce DC maturation. 
(A) IL-1 and IFNα stimulated CD8+ T cells (similar to OKT3 stimulation) induced DC maturation manifested by 
induction of CD83 and upregulation of CD86 expression. IL-18 and IFNα or OKT3 was added along with primed 
 
“Two signal” activated CD8+ T cells induce DC
Having established that the previously-primed CD8+ T cells can produce DC-activating 
cytokines in a non-TCR dependent manner (Fig. 1), we investigated the possibility of cross-tal
n alternatively-activated CD8+ T cells and immature dendritic cells (DCs). Addition of 
CD8+ T cells alone (data not shown) or the combination of IFNα and IL-18 to DC cultures did 
not result in maturation of DCs. In sharp contrast, addition of primed CD8+ T cells along with 
IFNα and IL-18, resulted in maturation of DCs (similar to TCR stimulation by antigen OKT3) as 
shown by induction of CD83 and high expression of CD86 (Fig. 5.2) These data demonstrate 
that in addition to the TCR-dependent activation, CD8+ T cells which have been activated by 







CD8+ T cells to day 6 DC cultures for 48 hours. The cultures were harvested and stained for DC maturation markers 
CD86 and CD83. Similar result was obtained in two additional experiments. 
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Alternatively activated CD8+ T cells induce type-1 polarized DC with enhanced IL-12p70-
producing capacity 
We next analyzed the impact of the alternatively activated CD8+ T cells on DC function.  To 
address D8+ T cells in the additional presence 
re harvested, washed and s L 
transfected J588 cells. As shown in Figure 5.3, DCs that were activated with combination of 
CD8+ T cells, IL-18 and IFNα produced high amounts of IL-12p70 upon subsequent stimulation. 
Similar to induction of DC maturation, type-1 polarization of DCs was observed only when 
CD8+ T cells were activated with IFNα and IL-18 or antigen OKT3. This observation 
demonstrates that alternative two signal-activated effector CD8+ T cells can exert 








Figure  5.3 Alternatively activated CD8+ T cells induce type-1 polarized DC with enhanced IL-12p70-
+
analyzed for IL-12p70 by ELISA. Results are representative for three independent experiments.
 this, immature DCs were cocultured with primed C
of IFNα and IL-18. After 48 hours, the cells we timulated with CD40
producing capacity. 
Day 6 DCs were cultured for 48 hours in the presence of CD8  T cells, OKT3, IL-18, IFNα or their combinations. 




he current data indicate that primed CD8+ T cells can be activated to perform 
their activation remains tightly 
atio by IL-2, IL-18, and IFNα or 
eir com
otential immunopathology caused by the presence of activated CD8+ T cells in a cytokine-rich 
nvironment.  
The phenomenon of alternative two-signal activation paradigm can partially explain the 
ystander activation and epitope spreading associated with autoimmune diseases, including 
ultiple sclerosis, diabetes, or arthritis (159-162). Intracellular pathogens such as viruses and 
mycobacteria can be strong inducers of pro-inflammatory cytokines like IFNα, IL-18 and IL-12, 
mbination can activate Th1 promoting function of CD8+ T cells in a non-specific 
Nγ and TNFα, creating 
T
immunomodulating activities in a TCR-independent fashion, 
controlled in an alternative two-signal activation paradigm. The efficacy of their alternative 
(cytokine-induced) “helper” function is dependent on the activation state of CD8+ T cells. In case 
of primed CD8+ T cells, the activation with “IL-18 + IFNα” was equivalent to the TCR-based 
activation. In contrast, no activation was observed when using unprimed CD8+ T cells. In 
addition to the “IL-18 + IFNα” signal, two other combinations – IL-15 + IL-18 and IFNα + 
K562 cells (or IFNα+ tumor cells) also elicited helper response in primed CD8+ T cells. In 
contrast to the effective activation of CD8+ T cells with “two-signals”, the same primed cells 
were not responsive to IL-15, IL-18 or IFNα  when used as single agents. Resting CD8+ T cells 
were resistant to all tested forms of the TCR-independent activ n 






bystander fashion. The cytokine-activated CD8+ T cells can secrete IF
cytokine environment that is conducive for maturation and type-1 polarization of DCs. This can 
enhance the probability of presentation of self epitopes in type-1 cytokine milieu and promote 
anti-self epitope spreading.  
+ 




alternative “two-signal” activation paradigm, depending on concomitant stimulation by at least 
two different cytokines. TCR independent induction of CD8+ T cell helper function can help in 
maintaining localized pro-inflammatory IFNγ-rich milieu and activation of DCs and thus 
promote immediate immune response before antigen-specific T cells undergo clonal expansion 
to carry out specific immune reaction. 
 
The alternative two-signal activation paradigm can explain the role of the CD8 T cells of 
unrelated antigen spec
data from mouse model of allergen induced airway inflammation indicate that resident memory 
CD8 T cells of unrelated specificity can suppress allergic inflammation in the airways in an 
antigen independent but IFNγ-dependent manner and involving IL-12 and IL-18 (163). Data 
from murine respiratory viral infections suggest that during secondary infections, lung-resident 
memory cells are likely to represent an early defense mechanism (164). Early production of IFNγ 
by memory CD8  T cells may be an outcome of stimulation by cytokines, when the viral load is 
still low.  
 In summary, our data indicate that the NK cell-like activity of CD8  T cells 








CD8 T cells are the effector cells essential for defense against intracellular pathogens and 
cancer. The priming of naïve CD8  T cells is a crucial step in the initiation of adaptive immunity, 
allowing the elimination of infected and transformed cells by the arising cytolytic effector CD8  
T cells and leading to generation of long-lived memory CD8  T cells. While the functionality of 
CTL responses. In contrast, memory CD8+ T cells perform positive 
immun
+ T cell is most often defined in terms of their cytolytic activity, here we have 
focused on the role of DCs in regulating the acquisition of effector phenotype (cytotoxicity and 
peripheral-tissue homing ability) and the immunoregulatory functions of the effector and 
memory CD8+ T cells.  
 The regulatory function of effector CD8+ T cells involves the perforin/granzyme B-
mediated killing of antigen-presenting DCs, as a negative feed-back mechanism limiting the 
magnitude of 
oregulatory functions, enhancing the DC expression of PI-9 (granzyme B inhibitor), thus 
promoting the survival of DCs by protecting them from CTL attack. This protective function of 
memory CD8+ T cells, analogous to CD4+ T cell-mediated DC protection, ensures that antigen 
presentation can continue in the presence of existing CTLs. Another important aspect of the 
“helper” function of memory CD8+ T cells is to provide DC-mediated polarizing signals for the 
development of CTL and CD4+ T cell responses. Our  findings from mouse experiments (see 
Chapter 2) show that OVA257-264-specific CD8+ T cell responses can both benefit from “helper 
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signals” delivered by memory cells (e.g. from LCMV-specific CD8+ T cells) and can act as a 
source of such signals. Consistent with this notion, the data indicate that CD8+ T cells of the 
same s
lls induced by a pre-immunization of wild type-animals, the most obvious source of  
“heterologous 
 data implicate the need of targeting different populations 
f “heterologous” helper T cells during the consecutive courses of vaccination in order to assure 
that each dose of vaccination targets a high proportion of resting (rather than activated by a prior 
vaccine dose) T cells.  
While helper function of memory CD8+ T cells can be exploited as a therapeutic strategy 
for treating cancer, in case of autoimmune conditions, inhibiting either the production or function 
pecificity can first benefit from “helper signals” delivered by memory T cells and, once 
having been enriched in the host and having achieved the memory stage, they can themselves act 
as a source of CD8+ T cell help. The current data indicate the possibility of enhancing the 
efficacy of the therapeutic vaccines for patients with cancer or chronic infections, by inclusion of 
pathogen/tumor-unrelated “heterologous” epitopes, that promote the interaction of vaccine-
carrying APCs with naturally occurring (or possibly artificially-induced) memory-type T cells. 
While in the current studies we have either used (in vitro) high numbers of resting CD8+ T cells 
from TCR-transgenic animals or have utilized (in vivo) the Granzymelow/CD62Lhigh memory 
CD8+ T ce
 CD8 help”  in cancer patients are the resting memory CD8+ T cells resulting from 
the vaccination-induced responses to “childhood diseases” or the infections that the patients have 
undergone in the past such as influenza, or HBV. Our data imply that the patients enrolled for 
therapeutic protocols involving “heterologous” helper epitopes will need to be screened for 
particular CD8+ T cell responses, to identify the appropriate memory-type CD8+ T cells and to 
avoid targeting of effector cells. An alternative approach may be to pre-immunize patients with 
unique immunogens. In either case, our
o
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of CD8+ T cell derived type-1 polarizing factors may be beneficial to the patients. Blocking of 
TNFα, one of the components of CD8+ T cell derived “helper signal”, using anti-TNFα 
antibodies (Infliximab) or soluble TNF receptor (Etanercept) has been a common treatment 
approach for diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease and 
psoriatic arthritis (165, 166). While the source of TNFα in these disease conditions is not clear, it 
+
ressor” stage of CD8+ T cell activation helps to explain the poor efficacy 
of vacc
remains to be tested whether the effectiveness of the drug is related to the inhibition of the helper 
activity of CD8  T cells. Although TNF blockers have helped to control chronic inflammatory 
conditions, they have also been shown to increase the risk of reactivation of tuberculosis, 
suggestive of the inability to promote and maintain effective type-1 immunity (167). Other 
potential strategies to inhibit CD8+ T cell driven type-1 immune responses can be blockade of 
the actions of IL-18 and IFNα/β, combination of these two cytokines can activate CD8+ T cells 
in the bystander fashion (see Chapter 5).  
The existence of a “supp
inations performed in therapeutic setting for chronic infections (130, 168), the reason 
being the likelihood of clearance of antigen-pulsed DC by the circulating terminally-
differentiated effector cells that predominate during chronic diseases. In addition, the current 
findings also help to explain the requirement for a delayed administration of booster doses of 
vaccination to prevent the phenomenon of CTL-mediated DC killing, thus achieving an optimal 
expansion of pathogen-specific CD8+ T cells and the effectiveness of vaccines. Given the role of 
PI-9 (endogenous granzyme B inhibitor) in protecting DCs from CTL-mediated killing, it is of 
potential therapeutic value to design membrane-permeable peptide mimetics of the reactive 
center loop (binding site for granzyme B) of PI-9, which will inhibit the functional activity of 
granzyme B. This can be potentially administered along with DC- or peptide-based vaccines to 
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prolong the life span of antigen-presenting DCs in conditions like cancer or chronic infections 
where effector cells predominate. This strategy will also aid in reducing the time-periods 
between primary and subsequent booster doses. 
 The ability of memory cells to support DC-mediated activation of additional CD8+ and 
CD4+ T cells suggests that the phenomenon of immune memory, in addition to qualitative 
changes in the activation requirements of memory cells, may also involve a different pattern of 
interaction of the existing CD8+ T cells with the antigen-carrying DCs. Our data support the 
following functional model of CD8+ T cell memory (Fig.6.1). During primary immune 
responses, DC activation requires release of factors representing pathogen-associated- or tissue 
damage-associated molecular patterns (PAMPs versus “danger signals” or DAMPs) (10, 11, 69), 
implicating the need for a significant pathogen load and tissue damage. In contrast, the activation 
of DCs during secondary responses can benefit from the activating signals released by high 
numbers of pathogen-specific memory-type CD8+ T cells, even before the destruction of the 
infected cells and the release of additional copies of the pathogen. Such memory CD8+ T cell-
dependent early DC activation helps the immune system to respond to the pathogen at much 
earlier stages of (re)infection, limiting its early spread, the extent of tissue damage and the 
activation of innate defense mechanisms, thus preventing the onset of disease symptoms.  
 Moreover, since during the primary responses, the PAMP- and DAMP-mediated DC 
protection from newly arising CTLs is limited to the period of active infection and ongoing 
tissue damage, the optimal activation of the T cells recruited to the lymph nodes at later stages of 
primary responses (needed for the optimal development of memory cells (126, 170) is dependent 


















Figure  6.1 Emerging model of CD8 help in the establishment of CD8+ T cell memory 
 Primary Response: Early stages of primary responses are characterized by significant pathogen load and 
by the thickness of arrow). In contrast, as primary response wanes and antigen presentation occurs in a reduced 
inflammatory environment, the absence of overt danger signals is compensated by CD4 T helper cells taking over the 
role of protecting DCs from CTLs and ensuring antigen presentation. Recall response: During secondary responses, 
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high numbers of established pathogen-specific memory CD8+ T cells can activate DCs at very early stages of 
infection prior to cell destruction and pathogen spread. In addition, memory CD8+ T cells can  protect DCs and thus 
g effector cells within 30 hours  in mice (38), and 3 days 




lts in human models and the previous 
in vivo observations in mouse from Franca Ronchese’s group (80), the same study also concludes 
allowing prolonged antigen presentation. This jump-starts the immune response and also prevents  onset of disease 
symptoms. Although memory cells can revert to DC-killin
vi .Tn: naïve CD8+ T cells, Teff : effector CD8+ T cells, Tm: memory CD8+ T cells. 
In contrast, during secondary immune responses, antigen-carrying DCs can also interact with 
the CD8+ memory T cells that are gradually recruited to the sites of (re)infection or to inflamed 
lymph nodes, limiting the dependence of antigen-carrying DCs on the pathogen-related or CD4+ 
T cell-related survival signals. Since the acquisition of effector functions by human blood-
circulating central memory CD8+ T cells requires up to 72 hours of activation and several cell 
divisions, the memory T cell-dependent DC protection during secondary immune responses can 
have substantial time-span.  
A recent report from Guarda et al (38) suggests that both effector and effector-memory 
populations of CD8+ T cells can eliminate the DCs in the “reactive” lymph nodes. While the 
observation that effector CD8+ T cells can eliminate antigen-carrying DCs supports similar 
earlier observations from several groups (80, 119), the location of DC killing is still unclear 
because of the conflicting data arising from different experimental models used to study the 
phenomena (37). The intravital two-photon microscopy used to image inflamed lymph
in e that effector CD8+ T cells traffic into “reactive” lymph node and kill antigen-bearing 
DCs. However, this study does not include a comparative analysis with peripheral tissues as a 
possible alternate site of killing, even though adoptive transfer of effectors is done prior to the 
injection of antigen-loaded DCs and thereby does not preclude DC-effector interaction in the 
peripheral tissues. In apparent contrast to our in vitro resu
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that effector-m mory T cells (Tem) can kill antigen-bearing DCs with similar efficacy as the 
effector cells. However, taking into consideration recent observations indicating the conversion 
of T  to Tem and Tem to effectors under conditions that favor migration to non-lymphoid tissues 
such as adoptive transfers alone or adoptive transfer followed by infection (171, 172), there is a 
need to reevaluate whether DC killing is performed by effector memory cells or by the arising 
secondary effector population. Nevertheless, in view of recent data regarding the lineage 
relationship between central-memory and effector-memory cells especially after memory cell 
reac ivation, it is essential to resolve the issue of relative contribution of different subsets of 
acti ated CD8+ T cells towards DC killing.  
The clarification of such relationship will allow reconciliation of the proposed killing of 
Ag-bearing DCs by memory CD8+ T cells with ample evidence that pre-existing memory T cells 
accelerate and amplify secondary immune responses, instead of preventing such responses. 
Similarly, problem exists with regards to the well-established efficacy of booster doses of 
vaccines. The data from human and mouse studies suggest that there is a lag period before 
memory CD8+ T cells can reacquire cytolytic activity (80, 127). In addition, using an in vitro 
human model, we have demonstrated that in memory cells granzyme B release is delayed  and 
preceded by secretion of cytokine TNFα which upregulates the granzyme B inhibitor PI-9 in 
DCs and thus in our hands memory CD8+ T cells did not exert immediate lytic activity against 
DCs. The existence of such a lag period, and the associated ability of recently activated memory 





CD8+ T cells to exert a helper, rather than DC-killing activity, can help expl
memory T cell function.  
While the successful induction of immune memory is believed to be essential for vaccine 
effectiveness, both the exact pathways of development of memory CD8+ T cells (in relation to 
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effector cells), and the features of their biology allowing them to expand and give rise to 
“effector” cells upon challenge with antigen, remain unclear. The current paradigm for 
successful vaccination is to include strong adjuvants along with peptide- or DC-based vaccines 
to induce a large effector T cell response, but it is not clear if this strategy will be equally 
suc
 CD8+ T cells into memory cells. Our results have implications not 
only fo
cessful for prophylactic and therapeutic vaccines. The reason being different requirements for 
prophylactic versus therapeutic vaccines, the goal of prophylactic vaccine is to generate large 
population of functional memory cells whereas the generation of a large effector T cell response 
is the immediate prerequisite for therapeutic vaccination. Following on this notion, our study 
identifies conditions of DC maturation that favor the cytolytic pathway of CD8+ T cell 
differentiation followed by the development of memory cells versus conditions that support 
direct differentiation of naïve
r better design of vaccines and vaccination regimens but also for understanding the factors 
that govern CD8+ T cell memory formation. 
While most studies have focused on the dose and persistence of antigen as determinants 
of CD8+ T cell activation and differentiation, there is considerable evidence from several groups 
suggesting that the CD8+ T cell’s potential to develop into effectors is influenced by the presence 
of inflammatory cytokines (IL-12, type-1 interferons) and the timing of naïve CD8+ T cell 
priming (early or late in acute infection).   
Recent studies by Harty and colleagues (76) have shown that coinjection of CpG ODNs 
(a potent inducer of inflammation) and an in vitro matured peptide-loaded DCs caused massive 
expansion of Ag-specific CD8+ T cells and their delayed conversion to memory phenotype. In 
agreement with these results, using in vitro human model for CD8+ T cell differentiation, we 
have found that induction of cytolytic function and tissue-homing ability required mature, 
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polarized DCs with the ability to produce high amounts of IL-12 family member cytokines. In 
contrast to the above scenario, we have also found that direct differentiation of naïve CD8+ T 
cells into memory cells occurred when DCs were matured but chronically activated and 
characterized by low production of cytokines belonging to IL-12 family. In accordance with our 
results, studies from murine models (48, 54-56) also suggest that manipulations to decrease the 
duration of infection and thus cause reduction in the inflammatory milieu, favor accelerated 
formation of memory cells. Immunization with in vitro-matured peptide-loaded DCs alone 
causes rapid formation of memory cells. Thus the collective theme is that the presence or 
absence of inflammatory signals affects the differentiation of naive CD8+ T cells. 
r, DC populations vary greatly in secondary lymphoid tissues during 
infectio
 Together these studies argue for the revision of the existing models of CD8+ T cell 
differentiation. In the currently proposed model (Fig 6.2), the decision making will depend on 
the cumulative strength of three signals- TCR, costimulation and inflammatory factors or 
cytokines. While TCR trigger and costimulation are sufficient to drive T cell proliferation, 
inflammatory signals are required for acquisition of effector and tissue homing functions. Thus at 
low signal strength and the absence of inflammatory signals, the potential of the naïve CD8+ T 
cell to develop into a memory cell is greatest. By contrast, at high signal strength combined with 
inflammatory signals, there is maximum potential for naïve cells to differentiate into effector T 
cells. During natural infections, the strength of inflammatory signal is related to the stage of 
infection. Early stages of infection are characterized by substantial amounts of PAMP-induced 
inflammatory mediators while waning stages of infection are associated with diminishing levels 
of inflammation. Moreove
n (173, 174) and thus the combination of DC-derived costimulatory signals and 
















there is a greater potential for naïve CD8  T cells to differentiate into effectors (thickness of the arrow denotes both 
+ mory cells is greatest. 
Figure  6.2 Emerging model of CD8+ T cell differentiation based on the role of inflammatory cytokines 
In the presence of both infection and inflammatory cytokines (during the early phases of primary immune response), 
+
increasing potential and inflammatory signals). In the absence or decreasing levels of inflammatory signals, the 
potential for naïve CD8 T cells to develop into me
 
We envisage a scenario in which naïve T cells recruited during early stages of infection 
will receive strong inflammatory signals and develop into effectors while those recruited in the 
later stages of infection could receive below-maximal stimulatory and inflammatory signals from 
exhausted DCs and thus be predisposed to give rise to long-lived memory cells (126).  
 103 
In summary, existing and emerging data from human and mouse models of infection 
suggest that its possible to selectively prime either memory or effector cells depending on the 
type of vaccination– prophylactic or therapeutic, by increasing or limiting DC activation and 
production of polarizing cytokines. The challenge will be to devise vaccination regimens such 
that the efficacy of successive booster immunizations is not compromised by the phenomena of 
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 Figure S 1b. Characterization of tissue-isolated effector CD8+ T cells and peripheral blood derived  




      
   
Figure S 2.  Naïve CD8+ T cells do not kill DCs but activate and induce maturation.  
Blood-is ated naïve CD8+ T cells induced DC maturation and primed them for high IL-12p70 production. SEB-
pulsed immature DCs (day 6) were co-incubated with blood-derived naive CD8+ T cells for 48 hours. Subsequently, 
DCs were harvested, their viability was assessed by staining with NAO and activation phenotype was analyzed by 
flow cyt etry for the expression of co-stimulatory molecule (CD86) and maturation-associated marker (CD83). 
The DCs also counted and stimulated with J588-CD40L to analyze their ability to produce IL-12p70. 
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ffector-type and memory-type CD8+ T cells were co-incubated for 4 hours with 51Cr labeled JY-1 cells (standard 







3b.  Effector-type CD8+ T cells kill immature DCs as shown by An




      
      
       
 
Figure S 3c. Short time restimulation of memory-type CD8+ T cells results in re-acquisition of the ability to 
kill immature DCs. Memory-type CD8+ T cells (day 14-16, no longer displaying DC killing function) were re-
Figure S 3a.  Both effector and memory type- CD8+ T cells kill SEB-loaded tumor cells.  
E
Cr-release
 S 3b 
 
Figure S nexin V staining. 
Effector-t e DCs (day 6) for 18-20 hours. 
S ently DCs were harvested, and their viability was assessed by Annexin V staining. 
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stimulated (48 hours) and co-incubated with SEB-pulsed immature DCs (day 6) for 18-20 hours. Subsequently, DCs 
     
    
     
were harvested and their viability was assessed by NAO staining. 
S 4a             
  
  
     
Figure S 4a. Fas-FasL interaction is not involved in CTL mediated DC killing.  
The presence of FasL antagonist (Fas-Fc) during co-culture of effector-type CD8+ T cells with immature DCs did 
not inhibit the killing of DCs as shown by NAO staining. 
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Figure S
 were pretreated with CMA and co-cultured with SEB-loaded 
DCs for -32 hours. Supernatants of CD8-DC co-culture were analyzed for cytokines IFNγ and TNFα by ELISA.  






 4b.  Unperturbed secretion of IFNγ and TNFα by effector-type CD8+ T cells, pre-treated with the 
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Figure S 7 Intracellular expression of Granzyme A in CD8+ T cells primed by sDC and DC1. 
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